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Summary 
 
In the course of this thesis, new molecular scaffolds based on tetraphenylporphyrin have 
been designed and synthesized, and their versatility has been studied by 
functionalization with various peptides.  
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The porphyrin scaffolds were successfully functionalized with peptides. Activation of 
the peptides required the use of N-hydroxysuccinimide, since other activants, such as 
PyBop, HOBt, HATU did not produce the desired results. The functionalization 
reaction can take place either in solution, or with the activated peptide still attached to 
the resin. Both Fmoc and Boc protected peptides could be used for functionalization of 
the scaffolds, as the porphyrin scaffolds proved to be stable in both deprotection 
protocols. No alteration of the peptide-porphyrin compound was observed during the 
synthesis. When stored at -20 ºC, the peptide-functionalized porphyrin compounds 
could be kept for a prolonged period of time. Stable MnIII-porphyrin complexes were 
obtained by insertion of manganese using MnIIAc2 in a 50% acetic acid/MeOH solution. 
 
An application of the functionalized scaffolds has been found in the design and 
synthesis of new inhibitors of thrombin, an enzyme of fundamental importance in the 
blood coagulation process. These inhibitors consist of a central porphyrin macrocycle 
bearing two different peptides; one of them is designed to interact with the thrombin 
catalytic site, while the other is designed to bind to the fibrinogen recognition site or 
exosite. The peptide sequences were designed using the structure of Hirunorm IV as 
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template, a synthetic peptide-based thrombin inhibitor that faithfully mimics the specific 
binding mode of hirudin, and is considered the most potent synthetic thrombin inhibitor 
known sofar. The sequence of the N-terminal tripeptide of Hirunorm IV, responsible for 
the interaction with the catalytic site, was left unaltered. The fibrinogen recognition site 
was accessible from the cis position as well as from the trans position, therefore, two 
new potential inhibitors have been proposed:  
 
 
 
 
 
 
 
 
             CS3-TAMPP-ES5                                               CS3-TAMPP-ES7 
 
The porphyrin ring offers many advantages, of which the insertion of a (paramagnetic 
or radio-active) metal ion in its centre could be of great interest for diagnostic purposes. 
The inhibitors CS3-TAMPP-ES5 and CS3-TAMPP-ES7, as well as their MnIII-
complexes, were able to interact with both the catalytic site and the exo site of 
thrombin. CS3-TAMPP, CS3-TAMPP-ES5, CS3-TAMPP-ES7 all had a Ki value of 1.0 
µM, whereas MnIII-CS3-TAMPP-ES5 had a slightly higher Ki of 1.6 µM. The presence 
of the peptides ES5 and ES7 did not affect the value of the inhibition constant.  
The inhibitors resulted to be very resistant against enzymatic degradation by thrombin, 
as after 24 h 85% of the original compound was still intact. Assays of inhibition of 
trypsin with the substrate BAEE proved the high selectivity of the new inhibitors. Even 
at elevated concentrations (up to 10 µM) the inhibitors did not affect the hydrolysis rate 
of the reaction. The interaction of the new inhibitors with the thrombin exo site by the 
peptides ES5 and ES7 was proved by fluorescence spectroscopy. The fluorescence of 
residue Trp148, in close proximity of the exo site, was quenched when the porphyrin-
based inhibitors were added. Addition of N-acetyl-hirudin54’-65’, an inhibitor of the 
exosite only with a high affinity for thrombin, displaced the inhibitor from the exo site, 
thus allowing the fluorescence intensity to return to almost its original level.  
The manganese complexes of the new inhibitors were capable of interacting with clot-
bound thrombin, and partially inhibited clot-growth in the presence of fresh fibrinogen. 
After 1h pre-incubation with a 10 µM inhibitor solution, clot growth was decreased to 
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60% compared to the uninhibited clots. The change of colour of the fibrin clot from 
white to yellow proved the presence of the inhibitors on the fibrin clot. 
 
To the best of our knowledge, the compounds MnIII-CS3-TAMPP-ES5 and MnIII-CS3-
TAMPP-ES7 are the first specific inhibitors of thrombin that might be employed for 
diagnostic purposes, due to the presence of a paramagnetic metal ion inside the 
porphyrin structure. The high stability against degradation by thrombin, and the high 
selectivity of these compounds make them extremely interesting for various 
applications. 
 
 
Chapter 1  Porphyrins as scaffold  
 
Introduction 
 
Porphyrins and porphyrin-related structures are widely diffused in nature, where they 
play important roles in various biological processes. They are most abundant in the so-
called heme proteins, proteins that contain one of the four naturally occurring hemes as 
prosthetic group1. The most common heme is heme b, the iron(II) complex of 
protoporphyrin-IX (shown in figure 1). The other hemes present slightly different 
substituents on the porphyrin ring.  
 
 
 
 
 
 
 
 
 
 
Figure 1: Structure of heme and two heme-proteins: myoglobin and cytochrome c peroxidase. 
 
Heme proteins carry out many different biological functions. The main function of the 
heme group is the retention of O2 and delivering it for enzymatic reactions. The iron 
atom of every heme group can bind one molecule of O2. For example, hemoglobin is a  
transporter of dioxygen, myoglobin is responsible for oxygen storage in living tissues, 
and peroxidases catalyze the breakdown of hydrogen peroxide to water. Other heme-
containing proteins include the catalases, oxidases, mono- and dioxygenases and the 
cytochromes, involved in electron transfer processes where the heme centres serve as 
one-electron carriers. 
 
Given the biological importance of these proteins, a large number of artificial model 
systems for their active sites has been developed in an attempt to (i) provide further 
insights for structure-activity relationships, (ii) understand the minimal requirements for 
function, (iii) reproduce the properties of the parent natural proteins in smaller 
molecules, and (iv) most importantly construct new, tailor-made molecules useful for 
biomedical, pharmaceutical, biological, and environmental applications2,3. In the search 
for these so-called low molecular weight heme-protein mimetics, the heme centre and 
Myoglobin Cytochrome c peroxidase Heme b 
related porphyrin structures have been extensively studied. From these studies has 
emerged that the porphyrin macrocycle presents several characteristics (mentioned in 
detail hereafter), that render it extremely suitable as building block for the design of 
larger molecular structures.  
 
The goal of this thesis is therefore to describe the synthesis of a multifunctional, 
porphyrin-based scaffold, carrying from one to four functional groups that allow a 
selective functionalization. Since we are mostly interested in the functionalization of 
these scaffolds with biomolecules, especially peptides, different peptides have been 
synthesized and linked to the porphyrin scaffolds. A possible application of these 
peptide-functionalized porphyrins can be found in the interaction with larger 
biomolecules such as proteins, enzymes or DNA, for example to interfere with certain 
biological processes. In our case, the peptides have been designed to interact with the 
active site of thrombin, an enzyme that is of fundamental importance for the blood 
coagulation process. The presence of the porphyrin scaffold should help to position the 
peptides in the correct orientation to bind simultaneously two different parts of the 
protein: the catalytic site and the substrate binding site. Moreover, the porphyrin ring 
can be a host for a variety of metal ions, including paramagnetic or radio-active metal 
ions, which allow the detection of the porphyrin-thrombin complex.  
 
 
1.1 Porphyrins 
 
1.1.1 Properties of the porphyrin macrocycle 
 
The basic structure of porphyrin (shown in figure 2) consists of four pyrrole-like five-
membered units, A, B, C and D, which are linked by four methine bridges, 5, 10, 15, 20 
(meso positions). The porphyrin macrocycle is an aromatic system containing 22 pi 
electrons, but only 18 of them are involved in a delocalization pathway. Porphyrin 
obeys Huckel's rule of aromaticity (4n + 2 pi electrons, n = 4) and is shown by X-ray 
crystallography to be planar. The aromatic character of porphyrins can also be seen by 
NMR spectroscopy. Due to the anisotropic effect from the porphyrin ring current, the 
NMR signals for the deshielded meso protons appear at low field (8 to 10 ppm), 
whereas the signals for the shielded protons (on the inner nitrogen atoms) appear at very 
high field (-2 to -4 ppm). 
 
 
 
 
 
 
 
Figure 2: Basic structure of the porphyrin macrocycle: numbering, functionalization sites and planarity. 
 
Meso-hydrogenated porphyrin derivatives, such as porphodimethanes and 
porphyrinogens (figure 3), are thermodynamically unfavourable, but their preparation 
by reduction of porphyrin is possible under anaerobic conditions and in the absence of 
light. Reduction of one of the pyrrole units on the porphyrin ring leads to a class of 
porphyrin derivatives called chlorins. Further reduction of chlorins gives another type of 
porphyrin derivative called bacteriochlorins, in which the reduced pyrrole units can be 
either diagonally opposite, or next to each other.  
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Figure 3: Hydroporphyrins. 
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The porphyrin ring is very stable to concentrated acids (e.g. sulphuric acid), and can act 
both as an acid and a base. Strong bases such as alkoxides can remove the two protons 
(pKa ~16) on the inner nitrogen atoms of a porphyrin to form a di-anion. On the other 
hand, the two free pyrrolenine nitrogen atoms (pKb ~9) can be protonated easily with 
acids such as trifluoroacetic acid. 
Porphyrins can undergo a number of chemical reactions typical of aromatic compounds. 
For example, electrophilic substitution reactions are often performed on porphyrins. The 
meso carbons and the β-pyrrolic carbons participate in these reactions. Furthermore, 
certain substituents on a porphyrin molecule can be modified. This leads to the 
availability of a variety of different porphyrins.  
 
1.1.2 Tetraphenylporphyrins 
 
Tetraphenylporphyrins (usually called TPP, 3D-structure shown in figure 4) are one of 
the most commonly used porphyrinic systems. They are easy to prepare, chemically 
very stable and their derivation has been well studied. Functional groups are usually 
placed on the ortho, meta and/or para positions of the phenyl groups. Because of steric 
hindrance the phenyl rings are positioned almost orthogonal to the equatorial porphyrin 
plane.  
   
 
Figure 4: 3D-structure of meso-tetraphenylporphyrin showing the  
                phenyl rings orthogonal to the porphyrin  plane. 
 
The presence of the phenyl groups enhances the rigidity of the overall complex, 
whereas functional groups on specific positions of the phenyl groups have defined 
orientations in space. Also, the tetraphenylporphyrin itself is soluble in various organic 
solvents, but anchoring of polar substituents to the functional groups dramatically 
enhances the solubility in polar solvents. The free porphyrin base has a deep red colour, 
whereas the corresponding acid has an intense green colour. 
 
1.1.3 Metalloporphyrins 
 
The porphyrin nucleus is a tetradentate ligand, in which the space available for a 
coordinated metal has a maximum diameter of approximately 3.7 Å. Upon coordination, 
the two protons on the pyrrolic nitrogen atoms are removed, leaving two negative 
charges4. Almost all metal ions form 1:1 complexes with porphyrin, only Na+, K+ and 
Li+ are known to form 2:1 complexes with one metal ion incorporated slightly below 
and the other above the porphyrin macrocycle plane. The geometry of the resulting 
porphyrin-metal complex and the presence or not of additional ligands depend on the 
metal ion5. For example, when CuII and NiII are incorporated in the porphyrin 
macrocycle, they generally display low affinity for additional ligands forming square 
planar complexes, whereas the chelates with MgII, CdII and ZnII readily combine with 
one more exogenous ligand (often corresponding to a solvent molecule) to form penta-
coordinated complexes with a square-pyramidal structure. Since these ions are slightly 
too large to fit perfectly into the porphyrin hole, they are positioned slightly out of the 
equatorial plane. Metalloporphyrins containing FeII, CoII or MnII are able to form 
distorted octahedral structures with two extra ligands. The coordination type, geometry 
and symmetry of several metalloporphyrin-complexes are summarized in table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 12: Coordination, geometry and symmetry of metalloporphyrins. CN = Coordination Number, P = 
                porphyrin, PhP = tetraphenylporphyrin, OEP = 2,3,7,8,12,13,17,18-octaethyl-21H,23H-porphin. 
 
 
 
 
1.1.4 UV-VIS spectrum of porphyrin 
 
In the UV-visible absorption spectrum, the highly conjugated porphyrin macrocycle 
shows intense absorption (extinction coefficient > 105) around 400 nm (the "Soret" 
band, B band or γ band), followed by several weaker absorption bands (Q bands or β-α 
bands) in the visible region6,7. The α band corresponds to the lowest porphyrin pi-pi* 
transition Q0, the β band to the vibronic envelope Qv. Since these transitions are 
polarized in the xy-plane of the porphyrin, both bands are split into two distinct bands, 
resulting in four Q bands, named I-IV in increasing intensity. Variations of the 
peripheral substituents on the porphyrin ring often cause minor changes in the intensity 
and wavelength of these absorptions. The UV-VIS spectra of meso-substituted 
porphyrins in which the substituent is an aromatic group, as is the case for 
tetraphenylporphyrins, display bathochromical shifts (even up to 20 nm) for all bands, 
as well as a change in the intensity sequence from Soret » α › β to Soret » β › α. 
 
            
 
Figure 5: Typical UV-VIS absorption spectrum of a porphyrin 
 
Upon formation of a metalloporphyrin, the two protons of the inner nitrogen atoms are 
lost. Due to the new D4h symmetry, the dipole transitions in the x and y directions are 
equivalent and both the Q0 and Qv transitions are doubly degenerate. As a result, the 
absorption spectrum of a metalloporphyrin usually displays only two bands in the 
visible region, whereas the Soret band can remain at its original position or shift to 
higher or lower energy. In some cases the insertion of a metal may cause new bands. 
The absorption spectra of metalloporphyrins can be classified into three types: regular 
or normal, hypso and hyper spectra.  
 
The ‘normal’ absorption spectrum 
 
Normal-type spectra are observed for a majority of metalloporphyrins where the 
relevant pi orbitals of the porphyrin macrocycle do not interact significantly with the 
metal pi orbitals (pz, dxz, dyz orbitals). The colour of these metalloporphyrins is deep 
purple. All closed-shell metal ions (d0 or d10) display this normal spectrum, in which the 
position of the α-band is around 570 nm, the β-band around 530 nm and the Soret band 
at 400 nm. In most cases the intensity sequence is Soret » α › β. Increasing atomic 
number of the metal within a given coordination type and set of axial ligands causes an 
additional small bathochromic shift. Also some lanthanoid ions (fn) display this normal-
type spectrum, apparently the extra electrons of these ions are too deeply buried to 
disturb the normal type. Almost all other metal ions with open electron shells give rise 
to ‘abnormal’ spectra.  
 
The ‘hypso’ spectrum 
 
The absorption spectra of d6-d9 metal ions follow the regular absorption pattern, but are 
blue shifted due to filled metal d (pi) to porphyrin eg  (pi*) back donation. This shift 
increases with increasing atomic number, as the back-bonding is more pronounced with 
heavier transition metals. The colour of these metal-porphyrin complexes varies from 
red to orange.  
 
The ‘hyper’ spectrum 
 
The hyper spectrum consists of more or less red-shifted α, β and Soret bands, and one or 
more additional bands. These spectra are caused by charge transfer transitions, more or 
less mixed with the porphyrin pi-pi* transitions, The number of extra bands varies from 
metal to metal, and the positions of the bands are far more dependent on the axial 
ligands than in the other spectrum types. The metal ions causing the hyper type spectra 
have the configurations d1-d5, the metalloporphyrin complexes are usually brown or 
green. Most of the metal ions belonging to this class can also have lower oxidation 
states within in the porphyrin, causing a normal or hypso spectrum (Cr, Mo, Mn, Fe, 
Os).  
 
 
Figure 6: Hypso (MnII) and hyper (MnIII) type spectra of Mn-tetraphenylporphyrin complexes8 
= MnII-TPP 
 
= MnIII-TPP(OAc) 
 The metalloporphyrin complexes with their metal oxidation numbers and corresponding 
spectral absorption types are summarized in table 2. 
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Table 2: Periodic table of metalloporphyrins. Spectral type: n = normal, h = hyper, y = hypso, o = no 
               spectrum reported. Ln = lanthanoids. The normal spectrum is bathochromically shifted in 
               monovalent metal ions as well as in B, Sr and Ba. 
 
1.1.5 Photochemistry 
 
Porphyrins and certain metalloporphyrins are excellent photosensitizers (light-absorbing 
molecules) because of similar energies of the singlet and triplet excited levels, high 
intersystem crossing yield and long triplet lifetime. The excited state porphyrins can be 
both donors and acceptors and form exciplexes [*Por+•D-•] or [*Por+•A-•], which then 
relax to the ground state or undergo chemical reaction. In acidic media or in the 
presence of reductants, porphyrins can be photoreduced to the dihydro, tetrahydro and 
hexahydro derivatives mentioned in paragraph 1.1.1. If an appropriate electron acceptor 
is available, the photo-excited porphyrin can transfer an electron. The acceptor may be 
an organic molecule, a metal complex or another porphyrin molecule. Since the reaction 
creates a charged species, polar media accelerate the process. The back reaction or other 
photosensitization processes such as 1O2 generation become favourable in nonpolar 
solvents.
1.2 Synthesis of porphyrins 
 
1.2.1 General synthesis 
 
There are two general approaches to obtain a desired porphyrin: (1) by modification of a 
naturally occurring porphyrin (e.g. heme); or (2) by total synthesis. Although 
convenient, modification of naturally occurring porphyrins poses great limitations on 
the choice of peripheral substituents because certain substituents cannot be easily 
modified. In most cases, such limitations can be overcome by total synthesis, which 
involves the syntheses of the pyrrole subunits having the required substituents. The 
following are the methods commonly used in porphyrin total synthesis9,10,11:  
• Condensation of pyrrole and (aryl)aldehydes  
• Mixed aldehyde condensation to give a mixture of porphyrins 
• 2 + 2 condensation of dipyrrylmethanes 
• 3 + 1 condensation of tripyrranes with diformylpyrroles 
• Stepwise synthesis leading to porphyrins bearing four different substituents 
• Cyclization of linear tetrapyrroles  
The simplest procedure to synthesize symmetrical meso-substituted porphyrins (e.g. 
tetraphenylporphyrin) consists of the acid-catalyzed condensation of pyrrole with a 
suitable aldehyde (scheme 1). The porphyrinogen formed in this reaction is 
subsequently oxidized to the corresponding porphyrin. This procedure was originally 
developed by Rothemund and Menotti in 1941 with an initial yield of 10%, reacting 
benzaldehyde and pyrrole in pyridine in a sealed tube at 150 ºC for 24 h12. The 
conditions were so severe that few substituted benzaldehydes could be converted to the 
corresponding porphyrin. An improvement were the modifications made by Adler and 
Longo, allowing benzaldehyde and pyrrole to react for 30 min in refluxing propionic 
acid (141 ºC) open to air13. These comparatively milder reaction conditions allowed a 
wider selection of substituted benzaldehydes to be converted to the corresponding 
porphyrins, in yields of up to 20%. β-substituted porphyrins could be obtained by using 
β-substituted pyrroles in the initial condensation reaction. However, this method still 
presented some problems, as the harsh conditions prevented the use of benzaldehydes 
bearing sensitive functional groups. Also, the product is invariably contaminated by the 
presence of reduced porphyrin (chlorin) in the reaction mixture, and the purification of 
the desired product can be complicated if it does not spontaneously crystallize or 
precipitate at the end of the reaction. A procedure with milder reaction conditions and 
higher yield has been developed by Lindsey and co-workers14,15, consisting of the 
reaction of pyrrole and (substituted) benzaldehydes in dichloromethane in the presence 
of a catalytic amount of acid, at room temperature and under nitrogen16. The resulting 
porphyrinogen is oxidized to the corresponding porphyrin by addition of 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ). Yields up to 45% can be obtained, depending on 
the type of substituent on the benzaldehyde.  
 
 
 
 
 
 
 
Asymmetrically substituted porphyrins can be synthesized by mixed aldehydes 
condensations. If a mixture of two different aldehyde starting products is employed in 
the Adler or Lindsey syntheses, a statistical mixture of porphyrin products is obtained 
(scheme 2). The obvious problem is the separation of the many products, which can 
include up to six different compounds that make large-scale syntheses virtually 
impossible. However, by varying the stoichiometry of the reagents, the yield of the 
desired product can be maximized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An alternative approach to the synthesis of substituted porphyrins is the 2 + 2 
condensation of dipyrrolic starting materials that can be dipyrromethenes, 
dipyrrylketones or dipyrryl-methanes. The first use of dipyrrylmethenes in porphyrin 
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synthesis was reported by Fisher in 1934, involving the self-condensation of 1-bromo-
9-methyldipyrromethenes in an organic acid melt (e.g. succinic acid) at temperatures up 
to 200 ºC. Although the yield of porphyrin was relatively high, only few substituted 
dipyrrylmethenes could withstand the severe reaction conditions. Dipyrrylmethanes 
were initially considered too unstable to be useful intermediates in porphyrin synthesis, 
but the milder reaction conditions developed by MacDonald and co-workers in 1960 led 
to the publication of the first dipyrrylmethane-based porphyrin synthesis (scheme 3)17. 
The condensation of a free dipyrrylmethane with a dipyrrylmethane dialdehyde was 
catalyzed by an acid catalyst, and the intermediate porphyrinogen oxidized by exposure 
to air to give the desired porphyrin. This route is widely used today also because the 
dipyrromethanes required for the MacDonald synthesis are often more easily prepared 
and purified than the corresponding dipyrromethenes. 
 
 
 
 
 
 
 
 
Variations on this method include the acid-catalyzed condensation of free 
dipyrrylmethanes with aldehydes to form porphyrinogens, which are subsequently 
oxidized to give the corresponding porphyrins (scheme 4). This route is widely used 
today due to its flexibility, and there are many reports of porphyrin synthesis based on 
this methodology. It is, however, very dependent on the availability of suitable 
dipyrromethane building blocks.  
 
 
 
The principal limitation of MacDonald’s ‘2+2’ approach is that one of the condensing 
units must be symmetrical, or two isomeric porphyrins will be produced. To overcome 
this limitation, the 3+1 synthetic route has been developed by Momenteau and co-
workers18,19. The 3+1 condensation involves the condensation of a tripyrrane (the 
tripyrrolic analogue of dipyrrylmethane, a compound containing three pyrrole groups 
linked alpha to the ring nitrogen atoms by two saturated carbons) with a diformylpyrrole 
in the presence of an acidic catalyst (scheme 5). Until the development of this 3+1 
method, tripyrranes had seen little application in the synthesis of porphyrin structures, 
although they had been widely utilized in the preparation of porphyrinoid derivatives in 
which a thiophene, furan or pyridine ring replaces one of the pyrrole rings20, as well as 
in the preparation of extended macrocycles such as sapphyrins21. The 3+1 procedure is 
particularly convenient if one of the components, either the tripyrrane or the 
diformylpyrrole, is symmetrical, or when the traditional 2+2 condensation encounters 
problems during the synthesis of the required dipyrrylmethanes22. This is, for example, 
the case for porphyrins bearing exocyclic rings such as phenanthrolinoporphyrins23 and 
acenaphthoporphyrins24. 
 
 
                
 
 
 
 
 
The stepwise synthesis of porphyrins bearing four different meso substituents (ABCD-
porphyrins) from dipyrrylmethanes was recently developed by Lindsey and co-
workers25,26. The procedure involves a total of 4 steps (scheme 6): a) preparation of a S-
2-pyridyl-substituted benzothiate; b) preparation of an unsymmetrical diacyl 
dipyrrylmethane by sequential acylation of a dipyrrylmethane with the S-2-pyridyl-
substituted benzothiate obtained in step a; c) reduction of the diacyl dipyrrylmethane to 
the corresponding dipyrrylmethane-dicarbinol using NaBH4; d) condensation of the 
dipyrrylmethane-dicarbinol with a new dipyrrylmethane followed by oxidation with 
DDQ to give the desired porphyrin. Although the yields for this type of reaction may 
vary from 15% to 40%, depending on the substituents on the meso-positions, the main 
advantage of this procedure is the absence of detectable scrambling in almost all cases. 
This greatly diminishes the usually extensive chromatography required for purification, 
and thus allows the production of significant quantities. Apart from the formation of 
ABCD-porphyrins, this rational synthesis can also be applied to the formation of A3B-, 
Scheme 5.  3 + 1 Condensation of tripyrrane with diformylpyrrole 
trans-AB2C-, cis-A2B2- and cis-A2BC-porphyrins. The only drawback is, again, the 
availability of suitable dipyrromethane building blocks. 
 
 
                                                
 
                    
 
                            
      
 
 
 
 
 
                         
 
                     
 
 
Linear tetrapyrroles (bilanes, bilenes or biladienes) can be cyclized to produce 
porphyrins (scheme 7)27. This procedure involves the multi-step condensation of 
pyrroles, after which the cyclization of the tetrapyrroles takes place in the presence of a 
transition metal. This strategy is mostly used when there is a need to synthesize 
porphyrins that are asymmetrical and contain a variety of substituents at the β-position. 
The most common tetrapyrroles used for porphyrin synthesis are 1,19-dimethyl-a,c-
biladienes and 1,19-dimethyl-b-bilenes. 
 
 
 
 
 
 
 
 
Instead of preparing the porphyrin macrocycle from reactants that already contain 
functional groups, another possibility is to introduce functional groups on a preformed 
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Scheme 7.  Cyclization of linear tetrapyrroles via b-bilenes 
Scheme 6.  Synthesis of ABCD-porphyrins 
porphyrin macrocycle. These functionalization reactions can be classified according to 
the reaction site on the porphyrin: 
  
- reactions at the meso-position 
- reactions at the ß position 
 
The meso- and ß-positions of the porphyrin macrocycle have similar reactivity towards 
electrophilic substitution, so the selective introduction of substituents at the meso-
positions commonly requires the use of ß-substituted porphyrins. Formylation at the 
meso-position is one of the most common reactions, but nitration and halogenation 
reactions are also known. The same reactions can be performed to functionalize the ß-
position, but again, to avoid a mixture of products, the meso-positions should be 
protected. Also, the exocyclic double bonds of porphyrins will undergo addition 
reactions, providing another method for the introduction of groups at the ß-positions. 
Oxidation of the ß-position leads to the formation of 1,2-diols. Depending on the 
functional groups introduced at the ß- and/or meso-positions of the porphyrin, further 
reactions can take place; these include intramolecular cyclization, functional group 
interconversions and functionalization of the phenyl groups of arylporphyrins. 
 
As is clear from the many different synthesis routes described above, there is not one 
perfect method to synthesize a specific porphyrin. The choice of the most convenient 
procedure depends heavily on the type of substituents required, as well as on the desired 
quantity needed. 
 
1.2.2 Insertion of metal ions 
 
Basically, the reaction between the metal ion and a porphyrinic compound consists of a) 
the formation of the equatorial MN4 plane; and b) the completion of the axial 
coordination sphere. However, certain considerations have to be made concerning the 
metalation procedure:  
 
1. The solvent for the reaction should be able to dissolve the porphyrin as well as 
the metal compound, but without coordinating the metal ion with high affinity in 
order to avoid competion with the porphyrin. 
 
2. The porphyrin has to be deprotonated in order to produce the negative P2- ion 
that is present in the metal-porphyrin complex. The presence of strong acids in 
the reaction media will impede or even reverse metalation by shifting the 
protonation/ deprotonation equilibrium to the left.  
 
 
3. To be able to react with the porphyrin macrocycle, the metal compound which 
carries the metal ion should dissociate, yielding an active (coordinatively 
unsaturated) species. Therefore, the metal complex should not be too stable 
otherwise it will not react with the porphyrin present in the reaction mixture. 
Other considerations are the availability, ease of handling, and solubility of the 
metal complexes in organic solvents. 
 
4. After the incorporation of a metal ion with a positive charge greater than +2, it 
will bind one or more anions from the reaction medium to form a neutral 
species. Some metal ions prefer certain defined geometries, which require the 
addition of a neutral ligand (solvent, H2O, O2) to complete their coordination 
sphere. 
 
The methods commonly used for the insertion of metal ions in the porphyrin 
macrocycle are listed below. The systems are characterized either by the solvent or the 
metal carrier used, depending on the more essential component. Since 
metalloporphyrins have characteristic UV-VIS properties, the reaction is usually 
monitored by spectrophotometry. 
 
The acetate method 
 
           Zn(OAc)2.xH2O + H2P                 Zn(P) + 2 HOAc + 2 H2O  
 
The acetate method includes all metalation reactions in which the protons of the 
porphyrin are transferred to acetate or propionate ions of the metal acetates/propionates. 
The solvents can be glacial acetic acid, or mixtures of CHCl3/MeOH. This method can 
be applied to all divalent metals, except those which are unstable in acetic acid, and to 
some tri- and tetravalent metal ions. Often sodium acetate is added to further buffer the 
solution and to enhance deprotonation of the porphyrins. This method is considered the 
method of choice for the synthesis of manganese-porphyrin complexes. 
 
H4(P)2+             H3(P)+              H2(P)              H(P)–             (P)2– 
HOAc 
 
100 ºC 
The pyridine method 
 
          Mg(ClO4)2 + H2P  + 4 Py               Mg(P)Py2 + 2 [PyH][ClO4] 
 
In those cases where the metalloporphyrin is very labile towards acids, the basic solvent 
pyridine is used for divalent metal ions. Pyridine is capable of dissolving the porphyrins 
as well as the metal salts, and the good complexing properties of pyridine allow the 
direct isolation of metalloporphyrin pyridinates. The same properties, however, impede 
the incorporation of metal ions with higher charges by forming pyridine complexes with 
the metal carrier, thus retarding the dissociation of the metal ion. 
 
The acetylacetonate method 
 
            Zr(acac)4 + H2P  + PhOH              Zr(P)(acac)OPh + 3 H(acac) 
 
The advantages of metal acetylacetonates as metal carriers are the ready availability, 
good solubility in organic solvents, easy manipulation, and the weakness of the acid 
liberated. Their only disadvantage lies in the stability of the chelated coordination 
sphere when metal ions of high charge and small size are used. Therefore, in many 
cases weakly acidic solvents like phenol or imidazole are necessary to generate more 
labile metal carriers. Nevertheless, this method is the method of choice to incorporate 
metal ions belonging to groups IIIa, IIIb, the lanthanides, and the early transition metal 
group. 
 
The phenoxide method 
 
              TaCl5 + H2P  + 3 PhOH              Ta(P)(OPh)3 + 5 HCl 
 
In some cases the acetylacetonates of early transition metals are missing. They can be 
incorporated using the metal oxides or chlorides in boiling phenol, as can 
acetylacetonates that are not reactive by themselves and need the phenoxides as 
intermediates. This method is especially recommended for the incorporation of Ta, Mo, 
W, and Re. 
 
The benzonitrile method 
 
                 PtCl2 + H2P  + 3 PhOH              Pt(P) + 2 HCl 
 
 
 
Py 
PhOH 
PhOH 
PhCN 
195 ºC 
Benzonitrile dissolves porphyrins at its boiling point, it is weakly coordinating and 
basic, and the high temperature assists in dissociating the high molecular aggregrates of 
some anhydrous metal halides that are otherwise unreactive or sparingly soluble. This 
method is excellent for PdII, PtII and Nb. 
 
The dimethylformamide method 
 
                 4 CrCl4 + 4 H2P  + O2              4 Cr(P)Cl + 2 H2O + 4 HCl 
 
Weakly coordinating, high boiling oxygen-donor solvents such as dimethylformamide, 
tetramethylurea and sulfolan are excellent solvents for the metal carriers and 
porphyrins. The best results have been obtained with anhydrous metal chlorides 
(although they can be difficult to obtain and to handle), as the high boiling temperature 
forces the formed HCl to escape.  
 
The metal organyl method 
 
                2 MeMgI + H2P              Mg(P) + MgI2 + 2 CH4 
 
Metal alkyls are the ideal metal carriers. In most cases they are Lewis acids, thereby 
promoting association with the porphyrin nitrogen atoms, but at the same time they 
provide very strong bases that easily accept the protons from the porphyrin. The 
reaction can therefore take place at rather low temperatures. The only disadvantage of 
this method is the problem concerning the synthesis and manipulation of the air- and 
moist sensitive metal alkyls and the related metal halides. 
 
The metal carbonyl method 
 
                Re2(CO)10 + H2P              [Re(CO)3]2(P) + H2 + 4 CO  
 
In metal carbonyls some of the CO groups may be eliminated, resulting in a 
coordinatively unsaturated species. This species acts as a Lewis acid, attacking the lone 
pairs of the porphyrin nitrogen atoms. This method is especially useful for the 
preparation of porphyrins containing the metals of groups VI to VIII.  
 
The metal alkoxide method 
 
                Ca(EtOH)2 + H2P              Ca(P) + 2 EtOH 
 
DMF 
 
153 ºC 
EtOH 
 
35 ºC 
decalin 
195 ºC 
Py/EtOH 
The very acid-labile metalloporphyrins containing CaII, SrII, BaII or alkali metal ions 
require a strongly basic medium.  
 
Obviously, the choice of an appropriate metalation procedure depends strongly on the 
type of functional groups and/or substituents present on the porphyrin macrocycle, and 
their sensitivity towards strong reagents and high temperatures. Especially for 
porphyrins functionalized with biomolecules, a less aggressive method should be 
followed in order not to disrupt the molecular structure.  
 
1.3 Applications of porphyrins  
 
1.3.1 Porphyrins as scaffold 
 
In many areas of organic, bioorganic and bioinorganic chemistry, small molecules are 
designed and synthesized to interact with large biomolecules such as proteins or DNA, 
or to perform and/or imitate certain enzymatic reactions. Whether the goal is to mimic a 
certain biological function or to design a potential new pharmaceutical compound, one 
of the major problems is reducing the flexibility of the new molecule, forcing it in the 
desired conformation. A rigid framework or scaffold is often used as a basic structure, 
upon which different substituents are introduced at the functional groups present on the 
scaffold. The use of macrocycles as scaffold is widely diffused, since their limited 
flexibility determines at least in part the orientation of the anchored molecules. 
Examples are cyclic peptides, peptide-based templates or organic macrocycles28 (figure 
7). 
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Figure 7: Examples of macrocyclic scaffolds: a) cyclic peptide; b) peptide based template; c) 
                   cyclotribenzylene, an organic macrocycle (R1,2 = functional group). 
 
The porphyrin macrocycle has several features that render it unique as potential 
scaffold29: 
 
- The rigidity of the porphyrin ring, allowing the design of a preorganized 
structure in which the groups anchored to the porphyrin framework display 
geometrically defined orientations. 
- The spectroscopic characteristics of the porphyrin ring, allowing the detection of 
small changes in the interaction with other molecules using UV-VIS 
spectroscopy, circular dichroism, NMR, fluorescence and Raman spectroscopy. 
- The presence of several distinct functionalization sites: the meso position, the β 
position and the inner nitrogens. 
- The possibility to incorporate various metal ions inside the planar structure, with 
characteristic redox chemistry at both metal and ligand. 
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 Due to their well-studied synthesis in combination with their many useful 
characteristics, porphyrins have found many applications in numerous research areas. 
 
1.3.2 MRI and photodynamic therapy 
 
Magnetic Resonance Imaging (MRI) is a non-invasive diagnostic technique, based on 
the generation of images of tissue hydrogen atoms (of water protons). To enhance the 
resolution of an MRI image, contrast agents are used, of which the unpaired electrons 
increase the velocity of relaxation of the water protons30,31. Usually paramagnetic 
metals such as GdIII and MnIII are used in contrast agent preparations, because of their 
elevated number of unpaired electrons. Although high concentrations of manganese are 
toxic for the organism, MnIII ions form strong chelates with porphyrins to give stable 
complexes with reduced toxicity. Synthetic tetraarylporphyrins incorporate the Mn ions 
tightly and are slowly metabolized; therefore they are good candidates for MRI. Several 
water-soluble metalloporphyrins have been developed as potential contrast agents for 
MRI and/or therapeutic purposes. Examples are MnIII-TPPS (tetraphenylporphyrin 
sulphonate)32 and 99mTc-CAP (cyclam acid porphyrin)33. 
Furthermore, it is known that several porphyrins and porphyrin derivatives can 
accumulate in malignant tumor tissue, even though the tumor-localizing activity of 
these compounds is not completely understood34,35,36. Besides using tumor-selective 
agents for localization and characterization purposes (diagnostics), they can also be of 
great importance for photodynamic therapy (also called PDT, photoirradiation therapy, 
phototherapy, or photochemotherapy), the treatment of cancer using the combination of 
light with a photosensitizing drug in an oxygen-rich environment37. Instead of light 
acting directly on tissue, a light-absorbing molecule (photosensitizer) is activated, upon 
which a photochemical reaction takes place. The photodynamic action is initiated by the 
absorption of a photon, bringing the photosensitizer in the excited singlet state, as 
shown in the Jablonski diagram (figure 8). From there, various relaxation processes are 
possible. The chromophore can relax back to the ground state by emitting a fluorescent 
photon [B], or to excited triplet states via intersystem crossing (ISC) [C]. From triplet 
excited states the chromophore can relax back to the ground state by emitting a 
phosphorescent photon [D] or transferring energy to another molecule via a 
radiationless transition [E]. Additionally, the chromophore can also lose energy through 
internal conversion or radiation-less transitions during collisions with other molecules 
[G]. In oxygenated environments the chromophore readily transfers its energy to 
ground-state molecular oxygen (3O2) to produce singlet oxygen (1O2), which can form 
adducts with organic substrates S(O) [F]. This often results in oxidation and degradation 
of vital biomolecules and eventually cell death38. Molecular oxygen thus plays a key 
role in propagation of the initial molecular damage. Ideally, a photosensitizer should 
display a high degree of selective accumulation in malignant tissue, in order to destroy 
the tumor tissue without effecting healthy tissues. 
 
      
 
 
 
 
 
 
Figure 8:   Jablonski diagram showing the various  modes of excitation and relaxation in a 
                  chromophore. 
 
Porphyrins, just as chlorins and bacteriochlorins, are very interesting as potential 
photosensitizers because, apart from their accumulation in tumor tissue, they are 
efficient singlet oxygen generators and have absorption maxima in the red portion of the 
electromagnetic spectrum (the Q-bands)39. Red absorption maxima allow activating 
light to penetrate deeper into tissue. The most commonly used and studied porphyrin-
based photosensitizer to date is Photofrin®, a hematoporphyrin derivative40. Clinically 
Photofrin® has exhibited no systemic toxicity and does not appear to be carcinogenic or 
mutagenic at the doses used. Photofrin® has been used successfully against a wide 
variety of cancers, does not appear to succumb to multidrug resistance, and Photofrin®-
PDT has no known cumulative dose ceiling as do radiation and chemotherapy. New 
porphyrin-based compounds have been synthesized in an attempt to create new and 
better photosensitizers. Even though many of them are photodynamically more active 
than Photofrin®, their pharmacological profile is usually less favourable and none of 
them have been legalized yet for clinical use. 
 
 
 
 
 
 
 
Figure 9: Structure of Photofrin® and new photosensitizers candidates. 
A = excitation 
B = fluorescence 
C = intersystem crossing  
D = phosphorescence 
E = non-radiative transfer of  
h    energy to singlet oxygen  
F = substrate oxidation by  
h    singlet oxygen 
G = internal conversion 
 
1.3.3 Interaction with DNA  
 
Chemical agents that bind and cleave nucleic acids are potentially useful as reagents for 
accessing structural and genetic information, as well as for development of efficient 
chemical nucleases. Such compounds may also be useful as drugs for treatment of 
cancer, genetic diseases, and viral infections. In general, free porphyrin bases and Cu2+ 
and Ni2+ complexes of meso-substituted cationic porphyrins are able to intercalate 
between the base pairs of the DNA (mostly at GC-rich regions), or bind in the minor 
groove by an outside binding mode (AT-rich regions). For Mn3+, Fe3+, Zn2+, and Co2+ 
complexes of these porphyrins, intercalation is blocked due to the presence of axially 
bound ligands and only outside binding occurs (AT-rich regions)41. Upon activation 
with light, porphyrins such as meso-tetra-(4-N-methylpyridyl)porphyrin (T4MPyP, 
figure 10) and related analogues also display the ability to irreversibly cleave DNA42,43.  
 
 
 
 
 
 
 
 
 
Figure 10: Structure of T4MpyP. 
 
The high affinity of these complexes for DNA and their ability to cleave single strand as 
well as double strand DNA, combined with the many useful characteristics of the 
porphyrin macrocycle, makes them highly interesting as a starting point for the 
development of new chemical nucleases. Recently, new compounds consisting of a 
porphyrin-anthraquinone conjugate have been synthesized that display wavelength 
dependent photonuclease activity44. 
 
1.3.4  Molecular recognition 
 
Molecular recognition, the ability of molecules to recognize and interact with each 
other, is a key element not only in many vital biological processes but also in current 
research areas, including drug design and synthesis, disease prevention, biomimetic 
chemistry, molecular catalysis, and the development of biomaterials and analytical 
sensors45,46. A striking feature of many of these biological and abiological processes is 
the very high selectivity between the ‘host’ and ‘guest’ molecules. Porphyrins are very 
attractive as potential sensors, since the binding of the analyte to a porphyrin (metal) 
center usually results in a detectable optical change, thus allowing a rapid analysis. 
Furthermore, the possibility to introduce polar groups on the hydrophobic surface of the 
porphyrin allows the use of the receptors in organic as well as aqueous media. The 
selectivity of the receptor can be increased by so-called multipoint recognition, where 
there is more contact area between host and guest and/or more interacting pairs of 
recognition groups. Once the first interaction has been established, the second and 
possibly even third interaction can take place easily. Multiple weak interactions are 
favoured over one strong interaction, because they result in high selectivity and fast 
association / dissociation kinetics. In case of a porphyrin receptor, the design of such a 
multipoint recognition is facilitated by the rigid framework, allowing the placement of 
suitable recognition groups on the periphery of the porphyrin macrocycle.  
One of the research topics in this area has focused on the incorporation of synthetic 
porphyrins and metalloporphyrins into a variety of material matrices, and substantial 
work has been done in the areas of solution and gas phase sensing. Considering the 
well-understood ability of heme to bind a variety of gases, such as NO, CO2 and O2, 
porphyrins are a suitable choice for the detection of gaseous species. Other applications 
of porphyrins as chemical sensors, besides the straightforward recognition of metal ions, 
involve the recognition of small biomolecules, such as amino acids, oligopeptides, 
nucleotides, saccharides and other small organic compounds47,48. 
 
1.3.5 Super-molecular assembly of porphyrins 
 
Super-molecular chemistry involves the assembly of organized entities, by means of the 
association of two or more molecular entities, for example through covalent bonds, 
electrostatic forces, or weak van der Waals interactions49. Due to their attractive 
structural features as well as their structure-sensitive spectroscopic, photophysical and 
electrochemical properties, porphyrins, porphyrin analogues and their corresponding 
metal / metalloid derivatives provide an extremely versatile synthetic building block for 
a variety of materials applications50. Synthetic multiporphyrin assemblies are mostly 
involved in materials science and nanotechnology (e.g. molecular-scale electronics, 
molecular wires, optical devices, sensors, data-storage)51. In particular, light-induced 
functions have attracted a great deal of interest, not in the least because of the potential 
of such aggregates to mimic the energy and electron transfer processes of the 
photosynthetic reaction center, providing better understanding of the photosynthesis.  
The super-molecular structures can vary from dimers to trimers to entire networks of 
porphyrins, in which the repeating units can be linked by a variety of bonds. These 
linkers can be subdivided in three types: nonmetallic covalent linkers (e.g. carbon-
nitrogen, carbon-oxygen, and carbon-carbon bonds), metal-ligand coordination52 (e.g., 
metal-oxygen and metal-nitrogen), and noncovalent linkers (e.g., hydrogen bonding, 
electrostatic, hydrophobic, hydrophilic, ð-ð, and van der Waals interactions)13. The 
linkages can be created between meso- or ß- pyrrolic carbons of each porphyrin, or 
between the substituents at these positions. An infinite number of complicated, highly 
organized three-dimensional structures can be synthesized, of which a few are reported 
in figure 11 to show some of the many possible variations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: From dimer and trimer to highly organized three-dimensional porphyrin networks53,54,55,56,57. 
 
1.3.6 Porphyrins as templates in de novo design 
 
The construction of novel proteins exhibiting functional properties similar to natural 
proteins represents one of the most challenging goals in biomimetic chemistry. The 
major problem is determining how to induce the desired three-dimensional structure in 
the polypeptide chain (the so-called ‘protein-folding problem’)58,59. To overcome the 
potentially complex folding patterns available to a polypeptide, peptides with 
predetermined secondary structures such as α-helices or β-sheets can be linked to a 
template60. The result is a ‘template-assembled synthetic protein’ or TASP. Many 
porphyrin-based templates are known to induce an α-helical folding in certain amino 
acid sequences61. A commonly encountered motif in many proteins is the four helix 
bundle, found in native enzymes like ferritin, tobacco mosaic virus, myohaemerythrin, 
haemerythrin, cytochrome c, cytochrome b562, as well as in methane mono-oxygenase. 
Extensive research has been done to imitate this particular type of folding. The 
stabilizing effect of porphyrin structures on helical bundles does not solely stem from 
the axial ligation of coordinating histidines. It has been shown that hydrophobic 
interactions between the (hydrophobic) surface of the porphyrin and the hydrophobic 
face of the helices also stabilize hemoproteins62,63. Examples are ‘helichrome’64, 
consisting of four identical 15-residue peptide chains linked to the four propionic 
groups of coporphyrin I, designed to mimic the hydroxylase activity of cytochrome P-
450, and ‘tetraphilin’, four 21-residue ion-channel forming peptides linked to a 
tetraphenylporphyrin, designed to serve as ion channel across the cell membrane 
(figure 12).    
 
                     
                                                                                              
 
 
 
 
 
 
 
 
Figure 12: Tetraphilin, a porphyrin-template-induced four helix bundle. 
1.4     Design of new porphyrin scaffolds 
 
1.4.1 Tetraphenylporphyrins bearing functional groups  
 
As basic structure for a new multifunctional scaffold that is to interact with 
biomolecules, we have chosen a tetraphenylporphyrin. This choice offers various 
advantages, among which the easy preparation and high stability of 
tetraphenylporphyrins, as well as the well-defined orientation of the substituents on the 
phenyl rings. The scaffolds bear from one to four functional groups (figure 13) on the 
para positions of the meso phenyl substituents, which is as far away from the porphyrin 
macrocycle as possible to avoid excessive steric hindrance in case of bulky substituents. 
Also, substitution on the para position has the advantage that the substituents occupy a 
defined position in space, whereas the orientation of the substituents on the ortho and 
meta positions are less defined due to rotation of the phenyl rings. 
 
         
 
 
 
 
             
 
 
 
 
 
 
 
 
 
Figure 13: Tetraphenylporphyrin scaffolds bearing from one to four functional groups. 
 
1.4.2 Choice of –CH2–NH2 as functional group 
There are various characteristics that make the amine group extremely suitable as 
functional group on the porphyrin scaffold. First of all, the easy introduction of the 
-NH2 group on the commercially available α-bromo-o-tolualdehyde using the well-
known Gabriel synthesis makes it an excellent precursor in porphyrin synthesis. The 
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Gabriel synthesis consists of three steps: 1) the reaction of phthalimide with KOH 
removes the N-H proton giving an imide ion, a good nucleophile, 2) the nucleophilic 
substitution by the imide ion on the alkyl halide generates the intermediate, N-alkyl 
phthalimide, 3) hydrolysis or hydrazinolysis liberates the primary alkyl amine. 
Since the object of these scaffolds is the functionalization with biomolecules, 
specifically with peptides, the presence of the amine groups is particularly useful 
because of the well-known coupling reaction with free carboxyl groups. Numerous 
activants are known for the formation of a peptide bond, but for these particular 
molecules the activation of the carboxyl group with N-hydroxysuccinimide in the 
presence of dicyclohexylcarbodiimide (DCC) appears to be the best choice (figure 14). 
Even though the activation reaction takes several hours, the activated peptide can be 
purified using HPLC, and stored for long periods of time at –20 °C without losing its 
reactivity65,66. Also, the activated peptide is capable of reacting with the amine group 
even in presence of H2O, while most activators, for example PyBop, HOBt, HATU, are 
de-activated in these conditions. Since porphyrins bearing amine groups tend to be quite 
hygroscopic, it is difficult to keep them in a completely dry environment. 
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Figure 14: Activation of the carboxyl group of a peptide (R) with N-hydroxysuccinimide in the presence 
                  of dicyclohexylcarbodiimide. 
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Figure 15: Reaction of the activated peptide with the amine group of the porphyrin scaffold 
 
If the peptide is supposed to bind with the N-terminal end to the scaffold instead of the 
C-terminus, a carboxyl group can be easily introduced either on the scaffold or on the 
N-terminus of the peptide using an appropriate spacer. An example is the reaction of the 
amine group with succinic anhydride in the presence of pyridine (shown in figure 16).  
 
R-NH2    + O
O
O
OH
O
H
N
O
R
pyridin
DMF
 
 
Figure 16: Reaction between the N-terminal of the peptide with succinic anhydride. 
 
When the porphyrin scaffold is designed to carry different peptides, it can be opportune 
to temporarily protect the remaining free amine groups during the coupling reaction 
with the first peptide. Although it is possible to obtain a large amount of the desired 
peptide-porphyrin compound by adding a deficient amount of the peptide, it is almost 
impossible to overcome the formation of small amounts of di, tri, and even tetrakis 
substituted porphyrin. Since this reaction is irreversible and would thus signify loss of 
the peptide as well as the scaffold, a preventive protection of the orthogonal groups is 
advisable, with subsequent deprotection after the reaction with the peptide has taken 
place. In peptide synthesis, the most widely used protection groups of the amine 
function are Boc and Fmoc, because of their straightforward synthesis, introduction and 
deprotection (figure 17). 
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 Introduction:  Boc-O-Su in DIEA/DMF           Introduction:  Fmoc-O-Su in DIEA/DMF 
Deprotection:  50% TFA in DCM           Deprotection:  20% piperidine in DCM 
 
Figure 17: Protecting groups for the amine function67,68. 
 
The choice of the protecting group depends on the peptide sequence, since it is 
advisable to avoid deprotection of other functional groups present in the sequence 
before finalization of the functionalized scaffold. For Fmoc-protected peptides a Boc 
protection of the scaffold is advised, and vice versa. The protection reaction takes place 
using Fmoc-O-Su or Boc-O-Su in DIEA, and usually produces a mixture of porphyrins, 
each containing a different number of protection groups. However, the desired 
porphyrin can be easily detected by mass spectroscopy and purified by HPLC or column 
chromatography. The protected scaffolds can easily be deprotected to obtain the original 
scaffold without loss of product, since the scaffolds are stable in both Fmoc and Boc 
deprotection protocols. 
R = porphyrin, peptide 
Chapter 2  Thrombin 
 
2.1 Biological function of thrombin 
 
2.1.1 The coagulation cascade 
 
Blood coagulation involves a series of enzymatic reactions known as the coagulation 
cascade69. In each of these reactions, an inactive pro-enzyme (also called coagulation 
factor) is converted to an active form, which then activates the next pro-enzyme in the 
series. The ultimate product of the coagulation process is thrombin, a highly specific 
serine protease of the chymotrypsin family. It is generated by proteolytic activation of 
the zymogen prothrombin, and plays a central role in the process of blood coagulation. 
Initiation of coagulation (also known as the extrinsic pathway of blood coagulation) is 
triggered by tissue factor (TF), a non-enzymatic lipoprotein constitutively expressed on 
the surface of cells that are not normally in contact with plasma. Upon injury, platelets 
start to aggregate at the site of injury and tissue factor is exposed to blood, where it 
functions as a receptor for activated coagulation factor VIIa (FVIIa) that circulates in 
plasma at a very low concentration. The complex formed between TF and FVIIa will 
then activate FIX and FX to FIXa and FXa, respectively. Although FXa is a poor 
activator of prothrombin (also called coagulation factor II or FII), enough thrombin is 
generated to initiate a series of new activation steps. Thrombin converts a small amount 
of fibrinogen (factor I) into fibrin strands that start to ‘precipitate’, stabilizing the 
primary platelet plug bound to the site of injury. The initial phase of the coagulation 
system generates only a small amount of thrombin, which, however, is sufficient to 
initiate fibrin formation and to start several thrombin-mediated feedback activations. 
 
 
 
Figure 1. The initiation phase of coagulation which, in the final stage, generates fibrin, which reinforces 
the primary platelet plug. Tissue factor (TF) in the subendothelium is exposed and binds to and forms a 
complex with FVIIa that circulates in plasma. This complex can activate FX to FXa, which converts 
prothrombin (FII) to thrombin (FIIa). Thrombin cleaves fibrinogen into fibrin for clot formation. This part 
of the coagulation system is also known as the extrinsic pathway. 
 
Thrombin generated during the initiation phase will then activate additional platelets 
and the coagulation factors V, VIII and XI. Activation of FV and FVIII is a very 
important step, as it will result in a huge amplification of thrombin generation. In order 
to localize thrombin generation to the site of injury, coagulation factor IXa (which has 
been activated by FXIa) is bound to phospholipids that are exposed on the membrane 
of activated platelets in the primary platelet plug. FIXa on the platelet membrane will 
then bind to its cofactor, FVIIIa, and form the tenase complex that is a potent activator 
of FX. Thus, FX can be activated via two pathways, first during the early initiation 
phase by FVIIa/TF complex, and then during the amplification phase (previously 
known as the intrinsic pathway) by the tenase complex. Activated FX will also, like 
FIXa, bind to the platelet membrane and together with its cofactor, FVa, form the 
prothrombinase complex which is a much more potent activator of prothrombin than 
FXa alone. More than 90% of the thrombin that is formed during coagulation is 
generated via the action of the tenase and prothrombinase complexes. 
 
 
 
 
 
 
 
Figure 2. The amplification phase of coagulation: In this phase, a number of new platelets are recruited, 
via thrombin activation, to the primary platelet plug. At the same time, thrombin generation is sharply 
amplified when the thrombin that was produced during the initial phase activates new coagulation factors 
in the amplification loop (FXI, FVIII and FV). 
In addition to fibrinogen activation, thrombin converts factor XIII to factor XIIIa, a 
highly specific transglutaminase that introduces cross-links composed of covalent 
bonds between the amide nitrogen of glutamines and the ε-amine group of lysines in 
the fibrin monomers, thus reinforcing the initial fibrin clot. 
2.1.2. Reaction of thrombin with fibrinogen 
The main function of thrombin in the coagulation cascade is the conversion of soluble 
fibrinogen to insoluble fibrin, thus forming a clot. The reaction between thrombin and 
fibrinogen is highly selective, as thrombin cleaves only 4 of the present 376 Arg/Lys-
Xaa peptide bonds. Fibrinogen consists of three pairs of polypeptide chains [(Aα,Bß,γ)2] 
covalently linked by disulfide bonds, and has a molecular weight of approximately 340 
kDa. Thrombin converts fibrinogen to fibrin monomers by cleaving fibrinopeptides A 
(16 amino acid residues) and B (14 amino acid residues) from the N-terminal ends of 
the Aα and Bβ chains, respectively. Removal of the fibrinopeptides allows the fibrin 
monomers to form a gel consisting of long polymers.  
 
 
 
Figure 3: Structure of fibrinogen 
 
     
    Figure 4: Fibrin polymerization 
 
Besides the conversion of fibrinogen to fibrin, thrombin also initiates further reactions 
that are of importance for blood coagulation70. It activates the clotting factors V and 
VIII required for prothrombin conversion and factor XIII, which stabilizes the formed 
fibrin clot71. Furthermore, thrombin induces the aggregation of platelets and is shown to 
have direct effects on the vascular endothelium and to mediate other nonhemostatic 
cellular events. Therefore, the inhibition of thrombin represents an effective interference 
in the coagulation process. 
 
2.1.3 Regulation of the coagulation cascade 
The coagulation system is regulated by the action of two endogenous plasma inhibitors: 
- TF pathway inhibitor (TFPI) inhibits the action of FXa via formation of a 
TFPI/FXa complex. This complex can also inhibit the TF/FVIIa complex, 
whereby the first step in the coagulation cascade is blocked. 
- The second inhibitor is antithrombin III (AT or ATIII), which despite its name 
is also a potent inhibitor of FXa. Antithrombin is a protein synthesized by liver 
and endothelial cells which binds and directly inactivates thrombin and other 
serine proteases (factors IXa, Xa and XIa).  The uncatalyzed reaction between 
the serine proteases and AT is relatively slow. The serine proteases still have 
time to generate thrombin and fibrin before becoming inactivated. However, in 
the presence of heparin or similar sulphated glycosaminoglycans, the reaction 
between AT and the serine proteases is virtually instantaneous resulting in the 
immediate blockage of fibrin formation. Normal endothelial cells express 
heparan sulphate (a sulphated glycosaminoglycan). Upon binding to this 
glycosaminoglycan, AT is able to inactivate any nearby serine proteases, thus 
preventing the formation of fibrin clot in undamaged areas. In the presence of 
heparin, thrombin is the primary target of AT. 
- Finally, coagulation and thrombin generation are also regulated by thrombin 
itself. Thrombomodulin (TM) is an endothelial cell protein that binds thrombin 
with high affinity. When thrombomodulin and thrombin form a complex, the 
conformation of the thrombin molecule is changed. This altered thrombin 
molecule now readily activates protein C to activated protein C (APC) and loses 
is platelet activating and protease activities. Protein C, together with its cofactor 
protein S, inhibits the formation of factors Va and VIIIa. Therefore, the binding 
of thrombomodulin to thrombin converts thrombin from a tremendously potent 
procoagulant into an anticoagulant. This is important in the normal 
physiological state because normal endothelial cells produce thrombomodulin 
that binds any circulating thrombin, thus preventing clot formation in 
undamaged vessels. APC finally degrades FVa and FVIIIa into inactive forms 
(FVai and FVIIIai) and the formation of tenase and thrombinase is terminated. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Regulation of the coagulation cascade 
 
The fibrinolytic system is responsible for dissolving fibrin and the eventual removal of 
the blood clot72. In the presence of fibrin and an enzyme called tissue plasminogen 
activator (t-PA), the pro-enzyme plasminogen is converted to plasmin. Streptokinase 
and urokinase plasminogen activator are also able to catalyze this conversion. 
Formation of plasmin is strictly located to the thrombus as both t-PA and plasminogen 
are bound to lysine residues that are exposed on partially degraded fibrin in a clot. 
Plasmin breaks fibrin into small soluble fractions known as fibrin degradation products 
(FDPs). There are several types of FDPs, since plasmin cleaves at multiple sites in the 
fibrin structure. Like coagulation, fibrinolysis is also carefully regulated. Alpha-2-
antiplasmin and alpha-2-macroglobulin are both proteins that bind to and inactivate 
plasmin.  
At any stage in the life of a blood clot, the amount of clot depends on the balance 
between the activity of coagulation and fibrinolysis. Excessive fibrinolysis can lead to 
haemorrhage (uncontrolled bleeding), whereas insufficient fibrinolysis and/or excessive 
thrombin activity could cause thrombosis: the formation of a fibrin clot (thrombus) 
capable of obstructing normal blood flow. The three phases of the haemostatic system, 
platelet aggregation, coagulation and fibrinolysis, are also termed primary, secondary 
and tertiary hemostasis. 
2.2 Structure of thrombin 
 
2.2.1 α, ß, γ thrombin 
The predominant form of thrombin in vivo is its zymogen, prothrombin (factor II), 
which is produced in the liver. The concentration of prothrombin in normal human 
plasma is ~5-10 mg/dl. Prothrombin is a glycoprotein with a glycan content of ~12%. 
It is cleaved in vivo by activated factor X, releasing the activation peptide and 
cleaving thrombin into light and heavy chains yielding catalytically active α-
thrombin. Alpha-thrombin consists of two peptide chains, where the A-chain of 36 
amino acids is linked by a disulfide bridge to the B-chain consisting of 259 amino 
acids. Alpha-thrombin is known to undergo autolysis upon long-term storage or 
proteolysis by trypsin or other enzymes, resulting in less active forms. These 
proteolyzed forms of α-thrombin have been termed β-thrombin and γ-thrombin73,74. 
β-thrombin is produced by the cleavage of the Arg-70 or the Arg-73 bond in the 
thrombin B-chain, whereas another form of proteolyzed thrombin, termed β'-
thrombin, is formed by the single cleavage of thrombin at Arg-15475. γ-thrombin is 
produced by proteolytic cleavage at both of these sites (Arg70/73 and Arg-154) in the 
B-chain. These cleavages cause the release of peptides that are no longer covalently 
attached to the thrombin molecule, but remain associated through ion exchange and 
gel filtration chromatography. However, eventually also ß and γ-thrombin are 
degraded into smaller peptides. Only naturally occurring α-thrombin possesses the 
ability to clot fibrinogen and induce the aggregation of platelets, but the proteolyzed 
forms of thrombin retain their ability to cleave small synthetic substrates, suggesting 
the active site remains essentially intact within both ß and γ thrombin76.  
 
 
 
Figure 6: Proteolyzed forms of α-thrombin. The degradation of α-thrombin to less active forms, either by 
autoproteolysis or limited trypsin digestion, is illustrated above. β-thrombin is generated by cleavage at 
Arg-70/73 in the thrombin B-chain, giving rise to the B1 and B2 peptides. γ-thrombin is generated from 
β-thrombin by the additional cleavage at Arg-154 of the B-chain, giving rise to the B4 and B5 peptides 
from the B2 peptide.  
 2.2.2 Crystal structure of human α-thrombin 
 
Serine proteases are proteolytic enzymes that all contain the characteristic serine-
histidine-aspartate catalytic triad [Ser195, His57, and Asp102 in thrombin]. The 
hydroxyl group of the serine acts as a nucleophile, targeting the scissile amide bond of 
the substrate. Thrombin is a glycosylated trypsin-like serine protease and, like trypsin, 
cleaves peptide bonds involving basic amino acid residues, most often arginine. 
However, unlike trypsin, it exhibits a marked specificity in cleaving only a very limited 
number of bonds in macromolecular substrates77,78. Although various three-dimensional 
models have been proposed for the thrombin B-chain based on sequence homology with 
bovine chymotrypsin and trypsin, the understanding of the specific and unique function 
of thrombin has been possible only since the determination of the first crystal structure 
in 1989 of the complex of α-thrombin with the specific inhibitor D-Phe-Pro-Arg 
chloromethylketone (PPACK)79,80, and the subsequently obtained crystal structures of 
thrombin complexes with various other inhibitors and/or substrates81.  
Thrombin can be described as an almost spherical molecule of approximate dimensions 
45Å x 45Å x 50Å, where the A- and B-chain are not organized in separate domains but 
form a single body, in which the A-chain is arranged in a boomerang like shape against 
the B-chain globule. The B-chain exhibits the characteristic polypeptide fold of trypsin-
like serine proteases, consisting essentially of two interacting six-stranded barrel-like 
domains of five helical segments, one helical turn and various surface-located turn 
structures. Though absent in other serine proteases, the A-chain, containing several 
turns and a helical segment at the C-terminal, resembles the propeptide of 
chymotrypsinogen and is similarly not involved in substrate and inhibitor binding. 
Because of the homology with the chymotrypsinogen sequence, the thrombin amino 
acid residues have been numbered according to the chymotrypsin sequence numbering. 
Insertion of amino acid residues is indicated by alphabetical subscripts. Also, for a 
better understanding of the various regions of the thrombin molecule, the amino acid 
residues of the substrate or inhibitor are named in respect to the peptide bond that is 
cleaved by the enzyme82. The residues on the N-terminal end of the cleavage site are 
indicated with P1, P2, P3, etc, whereas the residues on the C-terminal end are defined 
P1’, P2’, P3’. Consequently, the regions of the thrombin surface that interact with the 
respective residues are named S1, S2, S3 and S1’, S2’, S3’. 
The most remarkable difference with trypsin and chymotrypsin, apart from several 
inserted residues forming specific bulges or loops on the surface, 
number of charged residues, many of which are involved in internal as well as surface 
located salt-bridges. The negatively and positively charged residues are not distributed 
uniformly over the entire molecule, but are clustered to form a sandwich-like electric 
field distribution where the positive charges are mostly concentrated at two poles, 
whereas the negative charges are found in a ring-like arrangement, particularly around 
the active site. Furthermore, the catalytic site of human thrombin is deeper and more 
prominent than the trypsin catalytic site, due to the presence of two loops, the relatively 
rigid Trp60D loop and the slightly more flexible Trp148 loop. These loops physically 
restrict access to the active site pocket and stabilize interactions with appropriate 
substrates, thus explaining the exceptionally high specificity of thrombin for 
macromolecular substrates. In fact, mutants of human thrombin without the residues 
Glu146-Trp148 are definitely less specific in their interactions with serine protease 
inhibitors, emphasizing the fundamental role of this loop in substrate recognition83.  
 
Figure 7: Connolly surface of human α-thrombin with indication of the major interaction sites. 
 
Of the previously mentioned positively charged area’s, the region around loop Lys70-
Glu80 is of particular interest, containing nine positively charged residues in close 
proximity (Arg73, Arg75, Arg77A, Arg35, Lys149E, Lys81, Lys110, Lys109 and Lys36). The 
overall positive charge is only partially compensated by the presence of the negative 
charges of two Glu residues, Glu77 and Glu80, just beneath the surface. This region, also 
called exosite 1 or fibrinogen recognition site, not only binds fibrin and fibrinogen but is 
also known to bind negatively charged parts of several thrombin inhibitors such as 
hirudin and thrombomodulin, as well as the thrombin receptor. The electrostatic 
attraction makes sure the reactive (positively charged) domain of fibrinogen is in the 
right orientation to enter the catalytic site. The second positively charged region is 
centered around the residues Arg93, Arg126, Lys236 and Lys240, including the basic 
residues Arg97, Arg101, Arg165, Lys169, Arg173, Arg175, Arg233 and Lys235. In this region 
there are no negatively charged residues present below the surface to counteract the 
very strong positive electrostatic field. This site is also called the heparin-binding site, 
as it seems to be particularly suited to bind polyanions like the glycosaminoglycan 
heparin, a known thrombin inhibitor. Another interesting region in the human thrombin 
structure is the RGD segment (Arg187-Gly188-Asp189) beneath the specificity pocket, that 
probably plays an important part as docking site in platelet binding through the platelet 
specific integrin receptor GPIIb/IIIa.  
The complex of thrombin with the specific inhibitor D-Phe-Pro-Arg chloromethylketone 
has provided detailed information on the thrombin catalytic site. Analysis of the crystal 
structure of thrombin-PACKK complex shows the interaction of the S1-S3 sites of the 
enzyme with the various residues of the tripeptide inhibitor to be in an antiparallel 
fashion. The primary specificity site S1 of the enzyme, Asp189, forms a salt bridge with 
the basic residue in position P1 of the inhibitor (Arg3’) and is practically identical to the 
corresponding trypsin site, the only difference being the substitution of Ser190 in Ala, 
which renders the active site slightly less polar. The S2 site consists of two hydrophobic 
regions, both capable of hosting non polar residues of medium dimensions. The first 
hydrophobic region, formed by the residues His57, Ser214, Leu99, Tyr60A and Trp60D, 
accommodates the pyrrolidonic ring of P2 (Pro2’), whereas the second region, consisting 
of residues Ile174, Trp215 and the peptide segment 97-99, is occupied by the benzylic side 
chain of P3 (D-Phe1’). This second hydrophobic region, which is particularly adapted to 
accommodate aromatic residues, is usually called the aryl binding site to distinguish it 
from the first S2 site.  
 
2.2.3 Specific binding of fibrinogen 
 
Thrombin recognizes a number of natural substrates that are responsible for important 
physiologic functions. Its high specificity is controlled by residues within the active site, 
and by separate recognition sites located on the surface of the enzyme. As mentioned 
before, fibrinogen is the main substrate of thrombin. After removal of the 
fibrinopeptides A and B, the fibrin monomer remains and subsequently undergoes 
polymerization. The high specificity of thrombin for this substrate lies in the particular 
binding mode of fibrinogen to thrombin. The exosite 1 (also called fibrinogen 
recognition site) is the regulator of thrombin specificity and is believed to direct the 
reactive domain of the substrate to the active site of thrombin by electrostatic 
interactions. In fact, the positively charged exosite 1 interacts with the negatively 
charged C-terminal end of fibrinogen, as shown in figure 8. Besides interacting with 
fibrinogen, the exosite 1 is known to interact with numerous thrombin substrates, 
including FVIII, FV and the thrombin receptor. Other interactions with exosite 1 
mediate anticoagulant functions.  
The crystal structure of the complex of thrombin with a fibrinopeptide A analogue 
shows that the N-terminus of this peptide folds in a compact manner, bringing together 
hydrophobic residues so they can interact with the apolar region S284. In fact, fibrinogen 
residue Phe8 occupies the aryl-binding site of thrombin, adjacent to fibrinogen residues 
Leu9 and Val15 in the S2 subsite. The multiple hydrophobic interactions between 
fibrinogen and the thrombin surface provide an explanation for the narrow specificity of 
thrombin.  
 
 
Fig. 8:  Schematic diagram showing the major interactions of the fibrinogen Aα chain (orange) with 
thrombin. The boundary of the active-site cleft is depicted by a green dashed line. Hydrophobic 
interactions are dotted, acidic groups are depicted by red and basic groups by blue. The cleavage point is 
marked by an arrow. The Bß (blue) and γ (yellow) chains, linked by a disulphide knot () are shown in 
the neighbourhood of the fibrinogen-recognition exosite.  
 
2.2.4 Thrombin and fibrin 
 
Apart from binding fibrinogen, thrombin is also capable of specifically binding its 
product, fibrin, thereby limiting the amount of active protease that can reach the general 
circulation85,86. Fibrin serves as a reservoir of active thrombin, and has therefore 
historically been termed antithrombin I. Upon fibrinolysis, the bound thrombin is 
released while retaining its clotting activity. Thrombin that is bound to fibrin is 
protected from inhibition by antithrombin and heparin cofactor II, and still capable of 
cleaving fibrinogen, thus maintaining local procoagulant activity. Also, it can amplify 
its own generation by activating factors V, VIII and XI. The fibrin-binding ability of 
thrombin is thought to serve several purposes87. Clot forming is initially slowed, 
because the concentration of thrombin in solution is lowered. However, since most of 
the free thrombin is rapidly inactivated by several anticoagulant mechanisms, the bound 
thrombin secures a slow but constant activity around the site of injury. Degradation of 
the fibrin clot sets the bound thrombin free, resulting in new thrombin activity. The 
removal of the clot is therefore not rapidly, but slowly and gradually in order to avoid 
uncontrolled bleeding. 
 
 
 2.3 Natural inhibitors 
 
2.3.1 Inhibitors of thrombin in the coagulation cascade 
 
Generally speaking, serpins (serine proteinase inhibitors), a family of homologous, 
large (glyco)proteins, inhibit the action of their respective serine protease by mimicking 
the three-dimensional structure of the normal substrate of the protease. As a result, the 
serine protease binds the serpin instead of its normal substrate, blocking any further 
activity by the protease88.  
As mentioned before, the main direct inhibitors of thrombin in the coagulation cascade 
are thrombomodulin and antithrombin III. Other known inactivators are heparin 
cofactor II, protease nexin-1 and α2-macroglobulins.  
Of these inhibitors, antithrombin III (ATIII, also called heparin cofactor) is thought to 
be the most important physiological inhibitor of thrombin, even though it inhibits 
thrombin at a relatively slow rate. In fact, the glycosaminoglycans heparin and heparan 
sulphate accelerate the reaction by forming a trimolecular complex with thrombin and 
ATIII, thus increasing the inhibition rate at least a 1000-fold89. The binding to heparin 
induces a conformational change in the inhibitor, which renders its reactive site arginine 
more accessible to the active center serine residue of thrombin90.  Despite the fact that 
this inhibitor is known as antithrombin III, it is known to inhibit also other enzymes of 
the coagulation cascade, specifically factor Xa and IXa. The same dependence on the 
presence of glycosaminoglycans has been seen for a second inhibitor, heparin cofactor 
II (HCII), although the affinity of heparin for HCII is about ten-fold lower than for 
ATIII and the binding mechanisms are slightly different91. However, HCII is unique 
among serine protease inhibitors in its ability to be activated also by dermatan sulphate. 
In the absence of a glycosaminoglycan, HCII inhibits chymotrypsin more rapidly than 
thrombin, and does not inhibit other trypsin-like proteases of the coagulation pathway. 
This protease specificity is probably due to the presence of a leucine residue at the P1 
position of the reactive site, which is unusual for a thrombin substrate but seems to be 
essential for its inhibition of chymotrypsin92. The effective antithrombotic part of the 
heparin molecule is a pentasaccharide, crucial for the binding of antithrombin and for 
the fast anticoagulant activity of heparin. The heparin-inhibitor complex inhibits free 
circulating thrombin. Due to its large size, however, the complex is not able to inhibit 
thrombin that is already clot-bound.  
 
  
  
Figure 9: Structure of the pentasaccharide of heparin responsible for the binding to thrombin. 
 
Protease nexin-1 (PN-1) is a potent inhibitor of serine proteases present in vascular 
cells, and forms complexes with trypsin, thrombin, plasminogen activators, and 
plasmin93. PN-1 forms carboxylic ester links with serine proteases at their active site 
serine residues, a reaction that is characteristic of inhibitors in the antithrombin III/α1-
antitrypsin family. Also, like antithrombin III, heparin and heparan sulphate bind PN-1 
with high affinity, thus accelerating its binding to and inhibition of thrombin. A 
difference between these two proteases however lies in their site of action, whereas 
antithrombin III is active in plasma, PN-1 appears to be active mostly in non-vascular 
tissues94. 
Thrombomodulin is an endothelial cell surface glycoprotein that forms a 1:l complex 
with thrombin. Binding of thrombin to this high-affinity receptor alters its specificity 
toward several substrates95. The key contacts with thrombin are hydrophobic 
interactions between the side chains of residues Ile414 and Ile424 of thrombomodulin and 
the hydrophobic pocket on the thrombin surface96. A thrombin-thrombomodulin 
complex activates protein C approximately 1000-fold faster than thrombin alone. 
Activated protein C, together with cofactor protein S, degrades clotting factors Va and 
VIIIa, thus interfering in the coagulation cascade. 
The α2-macroglobulins are known to inhibit α- as well as ß-thrombin97. Besides being 
able to bind and inactivate thrombin, α2-macroglobulins are also capable of inducing 
the degradation of the subchains of fibrinogen. This fibrinolytic activity results in the 
formation of products whose structure resembles that of circulation fibrinogen 
catabolytes98. 
 
2.3.2 Hirudin 
 
Several natural anticoagulant agents have been found in haematophagous (blood-
sucking) parasites such as leeches and ticks, since they require to maintain blood 
fluidity during feeding and digestion. Hirudin, isolated from the salivary gland of the 
medicinal leech Hirudo medicinalis, is found to be one of the most potent natural 
inhibitors of thrombin (Ki = 0.3 pM), and certainly the most widely studied. Hirudin is a 
polypeptide of 65 amino acids that selectively binds thrombin in a 1:1 fashion, at the 
catalytic site as well as the fibrinogen recognition site. Because of the specificity of 
binding, hirudin does not inhibit other enzymes in the coagulation or fibrinolytic 
pathways, such as factor Xa, factor IXa, kallikrein, activated protein C, plasmin or 
tissue-type plasminogen activator. In contrast to heparin, hirudin: a) does not require 
antithrombin as a cofactor, b) is not inactivated by anti-heparin protein, c) has no direct 
effect on platelets, and d) is also capable of inactivating thrombin bound to clots or to 
subendothelium. 
Structural studies indicate that this inhibitor is composed of a compact N-terminal 
region, including residues 1-47 and cross-linked by three disulfide bridges, and a 
flexible negatively charged C-terminal tail that binds to the positively charged 
fibrinogen recognition site (exosite I) of thrombin99,100. The N-terminal domain covers 
the active site of thrombin and through its first three amino acids extensively penetrates 
into the specificity pockets of the enzyme, forming a parallel ß-sheet with thrombin 
segment Ser214-Gly219. The formation of the parallel ß-sheet by the N-terminal residues 
is the most remarkable feature of this particular binding, as opposed to the antiparallel 
binding fashion of fibrinogen and most thrombin inhibitors101. Also of great importance 
are the non-polar interactions with the hydrophobic regions of the thrombin surface, 
especially of the aromatic ring of Tyr3 that is buried in the aryl binding site. The many 
hirudin analogues that have been synthesized, containing one or more modificated 
residues, have proven the importance of the N-terminal region102. In fact, the N-terminal 
tripeptide makes approximately half of the total contacts observed for the binding of 
fragment 1-47 to thrombin103. The residues of the compact core, from Cys6 to Lys47, 
make only few contacts with thrombin when compared with the N- and C-terminal 
segments104. Of this central region, only 10 residues interact with the thrombin surface, 
with a total of 56 interactions. In contrast, the N-terminal pentapeptide and the C-
terminal tail are involved in 47 and 93 interactions with thrombin, respectively. 
The particular and highly specific binding mode of hirudin has been of great importance 
in the design of new, low molecular weight thrombin inhibitors. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.3 Haemadin 
 
Haemadin, a 57-amino acid peptide first identified in the saliva of the land-living leech 
Haemadipsa sylvestris, is very similar to hirudin105,106. The main difference between 
these two peptides lies in the binding location of their acidic C-terminal region107: 
whereas hirudin binds to the exosite I of thrombin, haemadin binds to the heparin 
binding site or exosite II.  Haemadin binds tightly to thrombin, and at physiological 
ionic strength is found to be a slightly stronger inhibitor of thrombin than hirudin. At 
infinite ionic strength, haemadin is even a six-fold stronger inhibitor, indicating that the 
formation of the human α-thrombin-haemadin complex is less dependent on ionic forces 
than it is for the human α-thrombin-hirudin complex. Like hirudin, haemadin binds to 
the active site of thrombin, with its N-terminus forming a parallel ß-sheet with thrombin 
residues Ser214-Gly216. Additionally, haemadin makes many other contacts with the 
active site, including a salt bridge between Arg2’ and Asp189 of thrombin in the S1 
pocket. The compact core of haemadin (residues 10-37) makes further interactions 
mainly through its A and C loops with the 60- and 96-loops of thrombin, while the 
acidic C-terminal tail covers the heparin binding site of thrombin (exosite II). As 
hirudin, haemadin is a very specific inhibitor of thrombin as it does not inhibit other 
proteinases.
Figure 10: Interaction mode of hirudin 
(variant 2, Lys47) with human α-thrombin, as 
obtained by X-ray analysis (PDB code 4htc). 
The thrombin Connolly surface is displayed in 
blue. 
Figure 1118: Schematic representation of the thrombin-
hirudin complex. The three N-terminal residues (1HI -
3HI) align with thrombin segment Ser214-Gly219 
through formation of a parallel ß-sheet. The reactive 
Ser195 is not blocked and the specificity pocket is filled 
with water molecules. The C-terminal tail loops 
around the characteristic thrombin insertion loop 
(Tyr60A- Trp60D) and binds to the fibrinogen binding 
exosite of thrombin via several salt bridges. 
2.4 Synthetic inhibitors of thrombin 
 
2.4.1 Synthetic inhibitors 
 
Since thrombin is one of the central enzymes of the coagulation cascade, it is also the 
most desirable target for interference in the blood coagulation process. Comparison of 
various crystal structures of thrombin and its complexes with low molecular weight 
inhibitors has indicated that the active site region changes but little upon binding of 
different ligands. Thus the thrombin structure provides an ideal starting point for 
computer graphics aided molecular design of structure based antithrombotic agents.  
Heparin and low molecular weight heparins (LMWH’s) inhibit both thrombin formation 
and thrombin activity by the activation of the natural inhibitor antithrombin III. Heparin 
is the most widely used anticoagulant in the treatment and prevention of thrombotic 
disorders, but it has limitations that reduce its clinical efficacy and safety108,109. The 
non-specific binding of heparin reduces its anticoagulant effect by binding to plasma 
proteins, platelet proteins, matrix proteins and endothelial cells, requiring constant 
monitoring of the patient to avoid undesired effects. Also, the heparin-ATIII complex is 
not able to inhibit thrombin bound to fibrin. Although the LMWH’s are more specific 
and do not bind proteins and subendothelial surfaces to the same amount as heparin, 
they are still unable to access clot-bound thrombin. The intensive search for new, 
specific inhibitors of thrombin has lead to the development of numerous synthetic 
inhibitors. These inhibitors can be divided into three distinct classes, based on their 
mechanism of action: 
 
-  Inhibitors of the catalytic site 
-  Inhibitors of the fibrinogen recognition site 
-  Multi-site inhibitors 
 
To be useful in the treatment of thrombotic disorders, a thrombin inhibitor has to be 
specific as it should not interfere with the activity of other serine proteases, which often 
have a structural homology to thrombin. Hirudin, being a highly specific inhibitor of 
thrombin with a unique binding mode, is therefore usually a starting point in the 
development of new inhibitors. 
 2.4.2  Inhibitors of the catalytic site 
 
Inhibitors of the catalytic site can be sub-divided in inhibitors of peptidic nature and 
inhibitors of non-peptidic nature. Inhibitors of peptidic nature can interact with the 
active site in a substrate mode, with their backbone antiparallel to the thrombin segment 
Ser214-Glu217, or in a non-substrate mode, in which their backbone is aligned parallel to 
this segment. 
Of the inhibitors of peptidic nature, the tripeptide D-Phe-Pro-Arg-H and its derivatives 
are the most widely studied. This tripeptide binds to the catalytic site of thrombin in an 
antiparallel fashion, in which the side-chain of Arg3’ is covalently linked to S1 residue 
Asp189, and residues Pro2’ and Phe1’ are found in the hydrophobic binding sites S2 and 
S3 respectively. The specificity of this short peptide for thrombin can be explained by 
the perfect fit of the three residues in the different sites the enzyme, resulting in a minor 
accessibility of the hydrophobic surface to the solvent as well as an optimal coupling 
between polar and charged residues. Although a very potent and selective inhibitor of 
thrombin, the peptide itself is rather unstable in neutral aqueous solution since it tends 
to cyclize and is thus inactivated. Therefore, numerous derivatives have been 
synthesized in which either the N- or the C-terminus is protected to prevent cyclization. 
The compound Boc-D-Phe-Pro-Arg-H is more stable than its parent peptide, but is less 
specific for thrombin since it inhibits plasmin as well. To maintain specificity, a series 
of N-alkyl derivatives have been synthesized of which the methyl derivative D-MePhe-
Pro-Arg-H has been found to be a potent and selective inhibitor of thrombin. The 
tripeptide chloromethyl ketone D-Phe-Pro-Arg-CH2Cl (PPACK) is one of the most 
widely known inhibitors, and its antithrombotic effects have been extensively studied. 
Other derivatives include D-Phe-Pro-Arg-CN and D-Phe-Pro-Arg-CF3.  
Peptides that bind in the parallel (hirudin-like) mode include BMS-186282 and BMS-
189090110. Among the the inhibitors of non-peptidic nature, NAPAP111, 4-TAPAP, 3-
TAPAP112 and MQPA113 all have inhibition constants in the nanomolar range. 
 
2.4.2 Inhibitors of the fibrinogen recognition site 
 
Inhibitors of the fibrinogen recognition site (exosite 1) have also been of great 
importance for the development of medicinal antithrombotics. These inhibitors block 
the binding site of fibrinogen, and thus inhibit its hydrolysis to fibrin. Since this type of 
inhibitor does not occupy the catalytic site, the enzyme retains the ability to cleave 
small substrates114. The starting compound for most exosite-1 inhibitors is the C-
terminal end of hirudin, more specifically the residues 53-65. Hirugen, N-acetyl-
hirudin53’-64’ with sulfatoTyr63, is a competitive inhibitor and has Ki values in the 
submicromolar range115. The desulfated hirugen still inhibits thrombin activity, but the 
binding affinity is decreased by an order of magnitude because the sulfate group is 
involved in an extended hydrogen bonding network utilizing all three sulfato oxygen 
atoms116. Derivatives of hirugen and of the C-terminal end of hirullin117, a hirudin-
related protein, have been extensively studied to increase the inhibition potential of 
these exosite 1 inhibitors.  
 
2.4.3 Multi-site inhibitors 
 
Multi-site inhibitors of thrombin combine the characteristics of the previously 
mentioned inhibitors, and bind the catalytic site as well as exosite 1. Not only do they 
block the conversion of fibrinogen to fibrin, but they also inhibit thrombin’s activity 
towards small substrates. These bifunctional inhibitors consist of an exosite 1 inhibitor 
linked by a flexible spacer to an inhibitor of the catalytic site, thus mimicking the 
interaction thrombin-hirudin. Hirulogs are a class of peptides in which an inhibitor of 
the catalytic site (the tripeptide D-Phe-Pro-Arg-H) and an inhibitor of exosite-1 
(residues 54-64 of hirudin) are linked by a poly-glycine spacer118,119. Various hirulogs 
have been synthesized, with different spacer lengths. The most promising inhibitor, 
hirulog1, presents a linker consisting of 4 glycine residues and has an inhibition 
constant in the nanomolar range. Hirutonins have a similar mechanism of binding, 
consisting of desolfo hirudin45-65 with amino acid modifications at the N-terminal 
end120. 
 
Hirunorms are peptide-based thrombin inhibitors consisting of 26 amino acids, 
rationally designed to mimic hirudins specific binding mode to thrombin121. The N-
terminal end interacts with the thrombin catalytic site in a non-substrate manner, 
connected by a three amino acid spacer to the C-terminal end, which specifically binds 
the fibrinogen recognition site. The crystal structures of the hirunorm-thrombin 
complexes confirm that their inhibitor binding mode is distinctive of a true hirudin 
mimetic122. The most potent hirunorms, IV and V, have inhibition constants in the 
picomolar range. 
 
 
  
 
 
Table 1: Structure comparison of hirudin and hirunorms 
2.5 Rational design of new thrombin inhibitors 
 
2.5.1 Peptide-functionalized tetraphenylporphyrin as potential inhibitor 
 
The most important interactions between hirudin and thrombin take place at the N- and 
C-terminal ends of hirudin, whereas its central part is mostly involved in hydrophobic 
interactions with the thrombin surface. This is shown by the development of many 
multi-site inhibitors of thrombin, of which the amino acids of the N-terminal part, 
responsible for the interaction with the catalytic site, are linked by an appropriate spacer 
to the amino acids of the C-terminal part, responsible for the interaction with exosite 1. 
Therefore, the replacement of the central part of the peptide-chain with a porphyrin 
scaffold should not have a large impact on the interaction with thrombin. The 
hydrophobic pocket that is present on the thrombin surface should be able to 
accommodate and interact with the porphyrin macrocycle. The porphyrin ring offers 
many advantages, of which the insertion of a (paramagnetic or radio-active) metal ion in 
its centre could be of great interest for diagnostic purposes. Although many synthetic 
inhibitors of thrombin are known, to the best of our knowledge no specific inhibitor of 
clot-bound thrombin has been developed that allows identification by non-invasive 
techniques, offering a unique chance to monitor and prevent excessive and possibly 
dangerous clot formation in the bloodstream. The binding to clot-bound thrombin is 
important not only to allow detection of fibrin clots, but also because the presence of 
thrombin circulating freely in blood is usually extremely low, and not enough to trigger 
a measurable response. 
 
2.5.2 Design of new porphyrin-based thrombin inhibitors 
 
Since hirunorms are considered the most potent synthetic thrombin inhibitors known, it 
has been a logical choice to use their amino acid sequence as template for the rational 
design of new thrombin inhibitors. Also, since the crystal structures of several 
thrombin-hirunorm complexes have been obtained and the specific binding mode of the 
hirunorms to thrombin has been extensively studied, computer graphics programmes 
can be of great help in the molecular design of new inhibitors. From the hirunorms I-V 
synthesized so far, hirunorm IV is proved to be the strongest inhibitor of thrombin, 
having an inhibition constant Ki in the picomolar range. The three amino acid sequence 
at the N-terminus (H-Chg-Arg-2Nal-), responsible for the interaction with the catalytic 
site, has therefore been left unaltered. Starting from the crystal structure of the 
thrombin-hirunorm IV complex, the tetrakis(p-(aminomethyl)phenyl)porphyrin has 
been introduced by the formation of a peptide bond between the carboxyl group of the 
N-terminal tripeptide and one of the porphyrin amine groups. It was observed that the 
fibrinogen recognition site was accessible from the cis position as well as from the trans 
position. Therefore, two new potential inhibitors have been proposed, the structures of 
which are shown in figure 12. Both inhibitors have the same amino acid sequence at the 
N-terminus, but differ in the peptide sequence that is supposed to interact with the 
fibrinogen recognition site.  
     
 
 
 
 
 
 
 
             trans           cis 
 
Figure 12: Structures of the newly designed porphyrin-based potential inhibitors of thrombin.  
 
The tripeptide H-Chg-Arg-Nal- is supposed to interact with the catalytic site just like 
hirunorm IV: The backbone of the tripeptide forms a short ß-strand parallel to thrombin 
main-chain residues Ser214-Gly219, with the Chg1’’ side chain filling the S2 subsite, Arg2’’ 
located at the entrance of S1, and the 2-Nal3’’ side chain occupying the aryl binding site. 
In case of the trans porphyrin, residue Trp148 (shown in figure 13) is involved in 
hydrophobic interactions with the porphyrin macrocycle. Also, one of the free amine 
groups has ionic interactions with Glu192, occupying the position of a water molecule in 
the original crystal structure. For the cis porphyrin these interactions are absent, as the 
porphyrin is positioned slightly outside the hydrophobic pocket present on the thrombin 
surface. Since the trans amine group is positioned further away from the exosite, the 
peptide H-Glu-Tyr-Asp-Pro-Chg-OH, interacting with the fibrinogen recognition site, is 
linked to the porphyrin by a spacer consisting of the segment HO-Succ-Pro-OH. The 
presence of succinic acid has a double function as it also serves to introduce a carboxy 
group on the N-terminal end of the peptide for the formation of a peptide bond with the 
porphyrin scaffold. The second peptide of the cis inhibitor is linked to the porphyrin 
scaffold by its C-terminal end, therefore an additional spacer is not required. 
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Figure 13: Specific interactions of the newly proposed inhibitors with the thrombin catalytic site and 
                   exosite 1. For the trans inhibitor: In pink the residues of particular interest for the binding of 
                    the inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
      trans           cis 
 
Figure 14: Space-filling model of the newly proposed inhibitors on the thrombin Connolly surface. For 
                    clarity the free aminomethyl groups on the porphyrin ring are omitted. 
 
Both inhibitors were designed with TAMPP as starting compound, but can also be 
synthesized using the cis and trans disubstituted tetraphenylporphyrins discussed in 
paragraph 1.4.1, which lack the presence of additional free amine groups.  
Trp148 
Chapter 3      Synthesis of the tetraphenylporphyrin scaffolds 
 
Introduction 
 
The following porphyrin scaffolds were synthesized, presenting from one to four 
aminomethyl groups on the para positions: 
 
 
 
         
 
 
 
 
  mono           di-trans              di-cis 
 
 
 
 
 
 
 
  tri           tetra 
 
The porphyrins, containing different numbers of functional groups, were initially 
synthesized using the mixed aldehyde condensation discussed in paragraph 1.3.1, by the 
reaction of benzaldehyde and 4-(formylbenzyl)phtalimide with pyrrole in the presence 
of TFA. Since our interest lies specifically in the cis and trans di-functionalized 
porphyrins, two other strategies have been attempted, to enhance the overall yields of 
these porphyrins. For the trans porphyrin, a 2+2 condensation of dipyrromethanes has 
been applied, by reacting 5-(4-phtalimidomethyl)phenyldipyrromethane with pyrrole in 
the presence of TFA. The synthesis of the cis isomer proved to be slightly more 
complicated, therefore a modified version of the ABCD-porphyrin synthesis has been 
applied.  
Furthermore, to obtain larger quantities of the tetrakis-(p-(aminomethyl)phenyl)-
porphyrin, two different methods were applied to synthesize the precursor tetrakis(p-
(phtalimidomethyl)phenyl)porphyrin: 1) direct synthesis by refluxing 4-(formylbenzyl)-
phtalimide and pyrrole in propionic acid, and 2) indirect synthesis by dissolving 
4-(formylbenzyl)phtalimide and 5-(4-phtalimidomethyl)phenyldipyrromethane in THF, 
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followed by addition of TFA. In all cases, the phtalimidyl groups were hydrolyzed by 
hydrazin to yield free aminomethyl groups. In case of the tetrakis-(p-(aminomethyl)-
phenyl)porphyrin scaffold, the aminomethyl groups were partially protected with the 
Boc protecting group in order to allow a selective functionalization of the scaffold. 
 
3.1 Results 
 
3.1.1  Synthesis of the porphyrin scaffolds  
 
The mixed aldehyde condensation of benzaldehyde and 4-(formylbenzyl)phtalimide 
was performed to obtain the porphyrins with different numbers of aminomethyl groups 
on the para positions of the meso phenyl groups. The intermediate 4-(formylbenzyl)-
bromide was synthesized on a 25 mmol scale by the reduction of α-bromo-p-tolunitrile 
under anaerobic conditions, using diisobutylaluminiumhydride (DIBAL) as reducing 
agent.  
 
The product, still containing traces of the starting material α-bromo-p-tolunitrile, was 
purified in part by recrystallization from hexane. The remainder was purified by column 
chromatography using eluent CHCl3 , and characterized by NMR. The yield was 79%. 
 
The intermediate 4-(formylbenzyl)phtalimide was formed by refluxing 4-(formyl-
benzyl)bromide with potassium phtalimide in DMF. 
 
The crude product was recrystallized from a mixture of CH2Cl2 and hexane and 
characterized by NMR. The yield was 84%. 
 
In the mixed aldehyde condensation, benzaldehyde and 4-(formylbenzyl)phtalimide 
reacted with pyrrole in the presence of TFA, to yield a mixture of porphyrins.  
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The products were separated by column chromatograpy using eluent CH2Cl2. The cis 
and trans isomers were inseparable by column chromatography and co-eluted with 
unreacted 4-(formylbenzyl)phtalimide, so a second purification step was needed, 
consisting of a second column chromatography using the eluent mixture hexane/ethyl 
acetate = 8/2. Separation of the isomers was possible by HPLC only after hydrolysis of 
the phtalimidyl groups. The identity of the products was determined by mass 
spectroscopy, the cis and trans isomers were distinguished by NMR. On a reaction scale 
of 0.2 mmol the following yields were obtained: TPP 3.9 %; mono 6.5 %; di-trans 4.0 
%; di-cis 6.0 %; tri 3.6 %. Only a small amount of the tetra-substituted porphyrin was 
formed, and the purification resulted complicated. However, for this particular scaffold 
an alternative synthesis was performed (see paragraph 3.1.4). 
 
3.1.2 Synthesis of trans di-substituted porphyrin 
 
To obtain a higher yield of the trans di-substituted porphyrin, the 2+2 condensation of 
5-(4-phtalimidomethyl)phenyldipyrromethane was applied. The intermediate 
5-(4-phtalimidomethyl)phenyldipyrromethane was synthesized by the condensation 
under nitrogen of  4-(formylbenzyl)phtalimide with pyrrole, using TFA as catalyst. 
 
The product was purified by flash chromatography to separate the dipyrromethane from 
polymeric byproducts, and characterized by NMR. The yield was 39%.  
 
The 2+2 condensation of 5-(4-phtalimidomethyl)phenyldipyrromethane to form 
10,20-di-phenyl-5,15-di(p-(aminomethyl)phenyl)porphyrin took place in two steps: 1) 
the condensation of 5-(4-phtalimidomethyl)phenyldipyrromethane with benzaldehyde in 
the presence of TFA; and 2) the hydrolysis of the phtalimidyl groups by hydrazine. 
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The product of the first reaction step was purified by column chromatography and 
identified by mass spectroscopy and NMR. The overall yield was 7 %. The hydrolysis 
of the phtalimidyl groups by hydrazin took place in TFE, the product was purified by 
centrifugation to remove the phtalimidyl salt. Mass spectroscopy confirmed the identity 
of the product, which was formed with a 91% yield. 
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3.1.3 Synthesis of cis di-substituted porphyrin  
 
It was also attempted to enhance the yield of the cis di-substituted porphyrin. However, 
this proved to be slightly more difficult than the synthesis of the trans isomer, due to the 
lesser symmetry of the molecule. A modified version of the classic ABCD-synthesis 
was developed, consisting of six steps (see scheme 1). 
 
Scheme 1: Modified ABCD-synthesis of cis-disubstituted porphyrin. 
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The first intermediate, S-2-pyridyl-4-benzothioate, was synthesized by mixing benzoyl 
chloride and 2-mercaptopyridine.  
 
The product was purified by recrystallization from hexane with a 80% yield, and 
characterized by NMR.  
 
The second reaction consisted of the condensation of benzaldehyde with pyrrole to form 
5-phenyldipyrromethane.  
 
The product was purified by repeated column chromatography, and characterized by 
NMR. The yield after various purifications was 51%.  
 
These two intermediates react in the presence of EtMgBr to form 1-benzoyl-
5-phenyldipyrromethane, which was purified  by flash chromatography.  
 
The product was characterized by NMR, the yield was 70%.  
 
Reduction of 1-benzoyl-5-phenyldipyrromethane yielded 1-benzyl-5-phenyldipyrro-
methanecarbinol.  
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Since this product was highly reactive, it was decided not to attempt further purification 
and use it directly for the next reaction step: the synthesis of  5,10-diphenyl-15,20-
bis(p-(phtalimidomethyl)phenyl))porphyrin by mixing the reactive carbinol, 4-(formyl-
benzyl)phtalimide and 5-(4-phtalimidomethyl)phenyldipyrromethane in the presence of 
TFA.  
 
This reaction yielded a mixture of porphyrins, which were purified by column 
chromatography and identified by mass spectroscopy. The formation of 
tetraphenylporphyrin and tetrakis(p-(phtalimidomethyl)phenyl)porphyrin, besides the 
desired 5,10-diphenyl-15,20-bis(p-(phtalimidomethyl)phenyl)porphyrin, was expected, 
but also small amounts of the mono and tri substituted porphyins were formed during 
this reaction. The overall yield of the cis substituted porphyrin was 8%. This product 
was hydrolyzed with hydrazine to give the final product, 5,10-diphenyl-15,20-bis(p-
(aminomethyl)phenyl)porphyrin, which was purified by HPLC. The yield of this final 
step was 88%.  
 
3.1.4 Synthesis of tetrakis(p-(aminomethyl)phenyl)porphyrin 
 
Two different strategies were followed to synthesize tetrakis(p-(aminomethyl)phenyl)-
porphyrin. The first strategy consisted of the condensation of 4-(formyl-
benzyl)phtalimide with pyrrole by refluxing in propionic acid.  
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The product was purified by repeated column chromatography, to remove all the 
polymeric byproducts that were formed during this reaction. The yield was 22%.  
 
The second strategy involved the condensation of 4-(formylbenzyl)phtalimide and 
4-(formylbenzyl)phtalimidyl dipyrromethane in the presence of acid. The product was 
purified by HPLC. The yield was 16,6%. 
 
 
 
 
 
 
 
The phtalimidyl groups were hydrolized with hydrazin as described previously. 
 
As mentioned before (see paragraph 1.1.2), the tetraphenylporphyrin base has a deep 
red colour in solution (absorption maximun 416 nm), whereas the corrisponding acid 
has an intense green colour (absorption maximum 434 nm). The solutions of  tetrakis-
(p-(aminomethyl)phenyl)porphyrin acid and base in EtOH are shown in figure 1, as well 
as their corresponding UV-VIS spectra. 
 
 
 
 
Figure 1: Solutions and UV-VIS spectra of tetrakis(p-(aminomethyl)phenyl)porphyrin in EtOH: 
                    Porphyrin base (red) and acid (green). 
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3.1.5 Protection of the amine function 
 
The scaffolds were designed to be functionalized with Fmoc protected peptides, 
therefore the amine groups were partially protected with Boc. The tetrakis-
(p-(aminomethyl)phenyl)porphyrin was protected by mixing 2 equivalents of Boc-O-Su 
in the presence of DIEA123. The result was a mixture of porphyrins. The ratio between 
the various porphyrin compounds could be manipulated by changing the ratio 
porphyrin/Boc-O-Su. 
 
 
 
 
 
 
 
The various porphyrins were purified by HPLC and the identity of the different products 
was determined by mass spectroscopy. NMR spectra were registered to establish the 
identity of the cis and trans isomers. The purified products were chemically stable and 
could be stored at -20 ºC for an  indefinite period of time. 
 
 
 
 
  
 
 
Figure 2: Chromatogram HPLC of the reaction between TAMPP and 2 eq Boc-O-Su. 
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3.2 Discussion 
 
The mixed aldehyde condensation of benzaldehyde and 4-(formylbenzyl)phtalimide in 
pyrrole yielded mono, di-trans, di-cis, and tri-substituted porphyrins, with average 
yields of 4-6%. No particular problems were encountered in the syntheses of the 
intermediates. The cis and trans di-substituted porphyrins were especially of interest, 
because of their application in the synthesis of potential inhibitors of the active site of 
thrombin. The yields of these porphyrins in the mixed aldehyde condensation were 
relatively low and the purification steps laborious, so it has been attempted to enhance 
the yield of these products by alternative strategies. The trans porphyrin was 
synthesized by a 2+2 condensation of 5-(4-phtalimidomethyl)phenyldipyrromethane, 
with a yield of 7%. The workup of this reaction using column chromatography was 
relatively easy. The synthesis of the cis compound resulted more complicated due to the 
lesser symmetry of the molecule. A modified version of the ABCD-porphyrin synthesis, 
consisting of six steps, was applied. Although the final condensation reaction had a 8% 
yield of cis porphyrin, the entire six-step synthesis required several laborious 
purifications and presented elevated costs. Therefore, for the synthesis of this particular 
scaffold the mixed aldehyde condensation might be a better choice.  
For the synthesis of tetrakis(p-(aminomethyl)phenyl)porphyrin, two different methods 
were applied: 1) the reaction of 4-(formylbenzyl)phtalimide and pyrrole in propionic 
acid, and 2) the TFA catalyzed condensation of 4-(formylbenzyl)phtalimide and 
5-(4-phtalimidomethyl)phenyldipyrromethane. Although this latter method had a lower 
yield (16.6% versus 22%), the reaction was relatively clean with almost no polymeric 
byproducts. The product could therefore be purified by HPLC, as opposed to the 
extensive column chromatography that was required in the first strategy to obtain the 
pure product. Therefore, for the synthesis of tetrakis(p-aminomethylphenyl)porphyrin 
the condensation of 4(-formylbenzyl)phtalimide and 5-(4-phtalimidomethyl)phenyl-
dipyrromethane is recommended. 
To allow a selective functionalization of the scaffolds, the aminomethyl groups were 
protected with the Boc protecting group by reacting the scaffold with Boc-O-Su in the 
presence of DIEA. The reaction was only performed for the tetrakis(p-(aminomethyl)-
phenyl)porphyrin, but could also be applied to the other scaffolds. The protected 
porphyrin scaffolds were stable and could easily be purified by HPLC. The Boc 
protecting groups could be removed with a 50% solution of TFA in CH2Cl2 to yield the 
original scaffold without loss of product. 
All scaffolds were stable in a wide range of solvents, and at different values of pH. 
Storage at –20 ºC for prolunged periods of time did not cause any alteration in the 
scaffolds.
3.3 Experimental section 
 
3.3.1 Materials and methods 
 
Unless otherwise stated, solvents of anhydroscan grade were used for all reactions. 
Reagents were obtained from commercial suppliers and used as received, with the 
exception of pyrrole that was distilled prior to use. All manipulations and reactions were 
carried out using standard Schlenk techniques. Analysis of reaction mixtures and 
products was performed by TLC on silica, or by using a RP-HPLC Shimadzu system 
LC-10AD VP with a spectrophotometric detector Diode Array SPD-M10A VP. Linear 
gradients were used of H2O 0.1% TFA and CH3CN 0.1% TFA. UV-VIS spectra were 
recorded on a Varian Cary 5000 spectrophotometer. 1H-NMR spectra were recorded on 
a Varian 200 MHz spectrometer. All spectra were referenced using the residual solvent 
peak as an internal standard (chloroform-d1 = 7.24, acetonitrile-d3 = 1.94). Mass 
spectrometry was carried out on a Voyager DEPRO MALDI-TOF spectrometer 
(Applied Biosystems) in the linear mode, using bovine insulin as internal calibration 
standard. The matrix α-cyano-4-hydroxycinnamic acid was recrystallized from EtOH / 
H2O prior to use. 
 
3.3.2 Synthesis of the intermediates 
 
Synthesis of 4-(formylbenzyl)bromide124 
 
A solution of 5.0 g (25 mmol) α-bromo-p-tolunitrile in 15 ml dry CH2Cl2 was degassed 
with nitrogen for 30 min. The reaction mixture was cooled to 0 ºC and slowly 25 ml of a 
1.0 M solution of diisobutylaluminiumhydride in CH2Cl2 was added. After refluxing for 
5 h, the reaction mixture was acidified till pH ~ 3 with a 10% sulfuric acid solution and 
stirring was continued overnight. The water layer was extracted three times with CH2Cl2 
after which the organic layers were collected and dried with Na2SO4. Evaporation of the 
solvent yielded a yellow solid, which according to TLC still contained traces of the 
starting product α-bromo-p-tolunitrile (eluent: CHCl3, RF tolunitrile = 9, RF aldehyde = 
8.5). After crystallization from hexane, 1.55 g (7.8 mmol, 31%) of pure white crystals 
was obtained. The remaining mixture of aldehyde and tolunitrile was purified by 
column chromatography (silica, eluent = CHCl3). The overall yield was 3.9 g (19 mmol, 
76%).
 
1H-NMR (200 MHz, CDCl3): δ 10.01 (s, 1H, O=CHA), 7.80 (d, 2H, Ar-HB), 7.60 (d, 
2H, Ar-HC), 4.45 (s, 2H, Br-CH2). 
 
 
 
 
 
 
 
 
Figure 3: The 1H-NMR spectrum of α-bromo-p-aldehyde in CD3Cl. 
 
Synthesis of 4-(formylbenzyl)phtalimide 
 
In a reaction vessel, 1.5 g (7.5 mmol) 4-(formylbenzyl)bromide and 1.4 g (7.5 mmol) 
potassium phtalimide in 60 ml DMF were refluxed for 4 h. After cooling to room 
temperature and evaporation of the solvent, water and CH2Cl2 were added and the water 
layer was extracted three times. The organic layers were collected, dried with Na2SO4 
and the solvent was evaporated. The resulting slightly yellow solid was recrystallized 
from a mixture of CH2Cl2 and hexane to yield 1.7 g of pure 4-(formylbenzyl)phtalimide 
(6.4 mmol, 84%). 
1H-NMR (200 MHz, CDCl3): δ 10.01 (s, 1H, O=CH), 7.90 (m, 4H, Ar-HB+E), 7.60 (m, 
4H, Ar-HC+F), 4.90 (s, 2H, N-CH2-Ar). 
 
 
 
 
 
 
 
 
 
Figure 4: The 1H-NMR spectrum of 4(-formylbenzyl)phtalimide in CD3Cl. 
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Synthesis of 5-(4-phtalimidomethyl)phenyldipyrromethane125 
 
To a mixture of 0.53 g (2 mmol) 4-(formylbenzyl)phtalimide and 5.5 ml (80 mmol) 
pyrrole under nitrogen, 15 µl (0.2 mmol) trifluoroacetic acid was added. The reaction 
was monitored by TLC (eluent: hexane/ethyl acetate = 1/1), where the 5-(4-phtalimido-
methyl)phenyldipyrromethane appeared at RF = 0.9. Byproducts (polymeric 
compounds) had minor RF values of 0,65 and 0,45. After 45 min the reaction was 
stopped by addition of 70 ml CH2Cl2 and 40 ml 1 M NaOH. The organic phase was 
washed several times with water, dried with Na2SO4 and evaporated to dryness. The 
resulting dark oil was purified by flash chromatography (silica, eluent: hexane/ethyl 
acetate), where the dipyrromethane eluted at ~ 40% ethyl acetate. After evaporation, 
0.29 g (0.76 mmol, 39%) of a yellow solid was obtained. 
1H-NMR (200 MHz, CD3CN): δ 7.89 (s, 2H, NH), 7.85-7.72 (2q, 4H, Ar-HA+B), 7.38 
(2d, 2H, Ar-HC), 7.16 (2d, 2H, Ar-HD), 6.66 (d, 2H, NH-CHG-), 6.12 (t, 2H, NH-CHF-
CH), 5.88 (d, 2H, NH-CHE-CH), 5.43 (s, 1H, meso), 4.83 (s, 2H, CH2). 
 
 
 
 
 
 
 
 
 
 
Figure 5: The 1H-NMR spectrum of 5-(4-phtalimidomethyl)phenyldipyrromethane in CD3Cl. 
 
3.3.3 Synthesis of the porphyrin scaffolds 
 
Mixed aldehyde condensation of benzaldehyde and 4-(formylbenzyl)phtalimide 
 
40.7 µl (0.4 mmol) benzaldehyde, 106 mg (0.4 mmol) 4-(formylbenzyl)phtalimide and 
55.3 µl  (0.8 mmol) pyrrole were dissolved in 40 ml CH2Cl2. TFA (30.6 µl, 0,4 mmol) 
was slowly added, upon which the reaction mixture slowly turned deep red. After 
stirring for 3 h, DDQ (363 mg, 1.6 mmol) was added to oxidize the formed 
porphyrinogen to porphyrin. The reaction was stopped when the HPLC chromatogram 
showed that the porphyrinogen had been completely oxidized. The solvent was 
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evaporated, the residue dissolved in CH2Cl2 and extracted with H2O. The crude product 
was purified first by filtration over alumina (eluent CH2Cl2, followed by MeOH), and 
subsequently by column chromatography using eluent CH2Cl2. The cis and trans 
isomers were inseparable and co-eluted with unreacted 4-(formylbenzyl)phtalimide. 
Therefore a second purification step was needed, consisting of another column 
chromatography using the eluent mixture hexane/ethyl acetate = 8/2. Separation of the 
isomers was possible by HPLC only after hydrolysis of the phtalimidyl groups with 
hydrazine. The identity of the products was determined by mass spectroscopy, the cis 
and trans isomers were distinguished by NMR. The yields of the products and their Rf 
values in 100%  CH2Cl2 are summarized in table 1. 
 
Compound Mass (Da) Yield (mg) Yield (µmol)    Yield (%) RF (CH2Cl2)  
 
     TPP                615.0          4.8           7.8                 3.9     0.95 
   mono      775.6      11.6       15.0         6.5     0.85  
  di-trans       933.0                 8.6                    9.2                   4.0        0.55 
  di-cis      933.0               12.8                  13.8            6.0      0.55 
     tri     1093.7      7.9        7.2         3.6     0.25 
 
Table 1: Products of the mixed aldehyde condensation. 
 
3.3.4 Synthesis of trans di-substituted porphyrin: 2+2 condensation126,127  
 
Step 1:  Synthesis of 10,20-diphenyl-5,15-di(p-(phtalimidomethyl)phenyl)porphyrin 
 
To a solution of 381 mg (1.0 mmol) 5-(4-phtalimidomethyl)phenyldipyrromethane and 
102 µl (1,0 mmol) benzaldehyde in 17 ml dry acetonitrile, 10 µl (0,13 mmol) TFA was 
added, upon which the reaction mixture immediately turned deep red. After stirring for 
15 h, 0.345 g (1.52 mmol) DDQ was added to oxidize the formed porphyrinogen to 
porphyrin. The reaction was stopped when the HPLC chromatogram showed the 
complete oxidation of the porphyrinogen. The solvent was evaporated, the residue 
dissolved in CH2Cl2 and extracted with H2O. The crude product was purified first by 
filtration over silica (eluent acetonitrile, followed by a solution MeOH/CH2Cl2 = 1/1), 
and subsequently by column chromatography using eluent CH3CN/CH2Cl2. The HPLC 
chromatogram showed the pure product with a retention time of 28 min. The identity of 
the product was confirmed by the 1H-NMR spectrum as well as by the mass spectrum 
(933.1 Da, calculated 933.0 Da). After evaporation of the solvent 31.2 mg (0.033 mmol) 
of a dark red solid was obtained. The overall yield was 7%.  
1H-NMR (200 MHz, CDCl3): δ 8.8 (s, 8H, HF), 8.2 (m, 8H, Ar-HD+E), 7.95 (m, 2H, Ar-
HB), 7.8 (m, 2H, Ar-HA), 7.78 (m, 10H, Ar-HG), 5.10 (s, 4H, CH2), -3.0 (s, 4H, NH). 
 
 
 
 
 
 
 
 
Figure 6: HPLC chromatogram and UV-VIS spectrum of 10,20-diphenyl-5,15-di(p-(phtalimidomethyl)-
                 phenyl)porphyrin. 
 
 
 
 
 
 
 
 
 
Figure 7: 1H-NMR spectrum of 10,20-diphenyl-5,15-di(p-(phtalimidomethyl)phenyl)porphyrin. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Mass spectrum of 10,20-diphenyl-5,15-di(p-(phtalimidomethyl)phenyl)porphyrin. 
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Step 2: Synthesis of 10,20-diphenyl-5,15-di(p-(aminomethyl)phenyl)porphyrin128 
  
The second step of this synthesis involved the hydrolysis of the phtalimidyl groups by 
hydrazine. The 10,20-diphenyl-5,15-di(p-(phtalimidomethyl)phenyl)porphyrin (31.2 
mg, 33 µmol) was dissolved in 7 ml THF and 243 µl (5.0 µmol) of hydrazine 
monohydrate was added. After stirring for 7 h, the solvent was evaporated and the 
residue dissolved in acetonitrile. The hydrazine salt was eliminated by centrifugation. 
The HPLC chromatogram showed the pure product with a retention time of 13.35 min. 
The mass spectrum confirmed the identity of the desired product (673.4 Da, calculated 
672.8 Da). Yield: 20.4 mg (30 µmol, 91%). 
 
 
 
 
 
 
 
 
Figure 9: HPLC chromatogram and UV-VIS spectrum of 10,20-diphenyl-5,15-di(p-(aminomethyl)-
                      phenyl)porphyrin. 
 
 
 
 
 
 
 
 
 
 
Figure 10: Mass spectrum of 10,20-diphenyl-5,15-di(p-(aminomethyl)phenyl)porphyrin. 
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3.3.5 Synthesis of cis di-substituted porphyrin: modified ABCD-porphyrin  
            synthesis 
 
Step 1: Synthesis of S-2-pyridyl-4-benzothioate129,130 
 
A solution of benzoyl chloride (581 µl, 5.0 mmol) in 10 ml CH2Cl2 was slowly added to 
a stirred solution of 0.55 g (5 mmol) 2-mercaptopyridine in 25 ml CH2Cl2. The reaction 
was monitored by TLC (eluent CHCl3/MeOH = 9/1) where the product had RF = 0.9. 
After circa 1 h the starting products had disappeared, and 30 ml 2.0 M NaOH was added 
to the reaction mixture. The organic phase was isolated, washed several times with 
water and dried over Na2SO4. Evaporation of the solvent yielded an orange oil. A 
minimum of ethyl acetate was added to dissolve the oil, after which the S-2-pyridyl-
4-benzothioate was precipitated with hexane. The resulting transparent crystals were 
washed several times with hexane and dried in vacuo. The 1H-NMR spectrum 
confirmed the identity of the product. Yield: 0.862 g (4.0 mmol, 80%). 
1H-NMR (200 MHz, CD3CN): δ 8.62 (d, 1H, HA), 8.00 (d, 2H, HE), 7.82 (d, 1H, HD), 
7.66 (m, 2H, HB+HC), 7.58 (t, 2H, HF), 7.40 (t, 1H, HG). 
 
 
 
 
 
 
 
 
 
 
Figure 11: 1H-NMR spectrum of S-2-pyridyl-4-benzothioate. 
 
Step 2: Synthesis of 5-phenyldipyrromethane131 
 
To a solution of 0.5 ml (5.0 mmol) benzaldehyde in 14 ml (200 mmol) pyrrole under 
nitrogen, a sample of TFA (8 µl, 0.1 mmol) was added. The reaction was monitored by 
TLC (eluent hexane/ethyl acetate = 8/2), where the desired product had RF = 0.45. After 
stirring for 40 min, the reaction was stopped by addition of 80 µl triethylamine in 100 
ml CH2Cl2. The organic phase was washed first with 1 M NaOH and subsequently three 
times with water. After drying with Na2SO4 and evaporation of the solvent, the crude 
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product was purified by column chromatography (silica gel, eluent hexane/ethyl 
acetate/triethylamine = 80/20/1. The identity of the pure product was confirmed by 1H-
NMR. The yield was 573 mg (2.6 mmol, 51%) of a white solid. 
1H-NMR (200 MHz, CD3CN): δ 8.89 (s, 2H, NH), 7.15-7.36 (m, 5H, Ar-H), 6.63 (t, 2H, 
HA), 6.00 (t, 2H, HB), 5.76 (d, 2H, HC), 5.41 (s, 1H, Hmeso). 
 
 
 
 
 
 
 
 
 
 
Figure 12: 1H-NMR spectrum of 5-phenyldipyrromethane. 
 
Step 3: Synthesis of 1-benzoyl-5-phenyldipyrromethane 
 
A solution of EtMgBr (1 ml, 1.0 M in THF) was added carefully via syringe to a stirred 
solution of 111 mg (0.5 mmol) 5-phenyldipyrromethane in 0.5 ml THF. The reaction 
mixture was cooled to –78 ºC and a solution of 107 mg (0.5 mmol) S-2-pyridyl-4-
benzothioate in 0.5 ml THF was added. The reaction mixture was kept at –78 ºC for 10 
min, and was then allowed to slowly reach room temperature. The reaction was 
monitored by TLC (eluent CH2Cl2/ethyl acetate = 25/1), where the desired product had 
RF = 0.7. After 45 min the reaction was quenched with a 1,0 M NH4Cl solution till pH 
~5/6. CH2Cl2 (10 ml) was added and the organic phase was washed several times with 
H2O, and dried with Na2SO4. Purification by flash column chromatography (silica, 
eluent from 100% CH2Cl2 to CH2Cl2/ethyl acetate 100/6) yielded a yellow oil (106 mg, 
0.35 mmol, 70%). The identity of the product was confirmed by 1H-NMR. 
1H-NMR (200 MHz, CD3CN): δ 10.0 (s, 1H, N-H), 9.0 (s, 1H, N-H), 7.8 (m, 2H, Ar-
HI), 7.55 (m, 3H, Ar-HJ), 7.25 (m, 5H, Ar-HE), 6.6 (d, 1H, HA), 6.4 (d, 1H, HG), 6.05 
(m, 2H, HB+F), 5.98 (t, 1H, HC), 5.6 (s, 1H, HD).   
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Figure 13: 1H-NMR spectrum of 1-benzoyl-5-phenyldipyrromethane. 
 
Step 4: Synthesis of 1-benzyl-5-phenyldipyrromethanecarbinol 
 
To a solution of 1-benzoyl-5-phenyldipyrromethane (98 mg, 0.3 mmol) in 6 ml 
THF/MeOH = 3/1, 25 equivalents of NaBH4 (7.5 mmol, 284 mg) were added. The 
reaction was monitored by TLC (eluent CH2Cl2/ethyl acetate = 100/4). The reaction was 
complete after 1 h, the reaction mixture was quenched with water (12 ml) and poured in 
15 ml CH2Cl2. After extracting three times with H2O, the organic layer was dried with 
K2CO3 and the solvent evaporated to yield an orange oil. Due to the high reactivity of 
this product, it was used immediately for step 5 of this synthesis, without ulterior 
purification steps. Therefore, no characterization of the product was performed. 
 
Step 5: Synthesis of 5,10-diphenyl-15,20-bis(p-(phtalimidomethyl)phenyl)porphyrin 
 
1-benzyl-5-phenyldipyrromethanecarbinol (98.5 mg, 0.3 mmol), 5-(4-phtalimido-
methyl)phenyldipyrromethane (114 mg, 0.3 mmol) and 4-(formylbenzyl)phtalimide 
(79.6 mg, 0.3 mmol) were dissolved in 60 ml acetonitrile. To this solution, TFA (138 µl, 
1.8 mmol) was added in aliquots of 10 µl. The reaction mixture instantly turned deep 
red. After stirring for 1 h, 2 equivalents of DDQ (136 mg, 0.6 mmol) were added and 
stirring was continued for 2 h. Triethylamine (251 µl, 1.8 mmol) was added and the 
entire reaction mixture was filtered through a pad of alumina (eluted with CH2Cl2) until 
the eluent was no longer dark. Removal of the solvent gave a dark solid, which was 
purified by column chromatography (silica, 100% CH2Cl2).  
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Three different porphyrins were eluted with the following RF values (characterization by 
mass spectroscopy):  
 
0,95 =   tetraphenylporphyrin (9.34 mg, 15 µmol, 5.1%), mass spectrum 615.8 Da 
                (calculated 614.7 Da);  
0,80  =   (p-(phtalimidomethyl)phenyl)triphenylporphyrin (14.8 mg, 19 µmol, 6.4%), 
                mass spectrum 776.1 (calculated 774.5);  
0,65  =  5,10-diphenyl-15,20-bis(p-(phtalimidomethyl)phenyl)porphyrin (22.5 mg, 24 
                µmol, 8.0%), mass spectrum 935.4 (calculated 933.0). 
 
 
 
 
 
 
 
 
Figure 14:  HPLC chromatogram and UV-VIS spectrum of 5,10-diphenyl-15,20-bis(p-(phtalimido-
                   methyl)phenyl)porphyrin. 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Mass spectrum of 5,10-diphenyl-15,20-bis(p-(phtalimidomethyl)phenyl)porphyrin. 
  
Step 6: Synthesis of 5,10-diphenyl-15,20-bis(p-(aminomethyl)phenyl)porphyrin 
 
22.5 mg (24 µmol) 10,20-diphenyl-5,15-bis(p-(phtalimidomethyl)phenyl)porphyrin was 
dissolved in 5 ml THF and 175 µl (0.0036 mmol) of hydrazine monohydrate was added. 
The reaction was monitored by HPLC, were slowly a new peak at 17.1 min started to 
form while the original porphyrin at 28.7 min slowly disappeared. When the reaction 
was complete, the solvent was evaporated, the residue was dissolved in acetonitrile and 
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the hydrazine salt was eliminated by centrifugation. The crude product was purified by 
HPLC. The mass spectrum confirmed the identity of the desired product (674.2 Da, 
calculated 672.8 Da). Yield: 14.2 mg (21 µmol, 88%). 
 
 
 
 
 
 
 
 
 
 
Figure 16: HPLC chromatogram and UV-VIS spectrum of 5,10-diphenyl-15,20-bis(p-(aminomethyl)-
                  phenyl)porphyrin. 
 
 
 
 
 
 
 
 
 
Figure 17: Mass spectrum of 5,10-diphenyl-15,20-bis(p-(aminomethyl)phenyl)porphyrin. 
 
3.3.6 Synthesis of tetrakis(p-(aminomethyl)phenyl)porphyrin  
 
1)   Reaction between 4-(formylbenzyl)phtalimide and pyrrole 
 
1.46 g (5.5 mmol) 4(-formylbenzyl)phtalimide and 0.36 ml (5.5 mmol) pyrrole were 
dissolved in 20 ml propionic acid and refluxed for 30 min. After cooling to room 
temperature, the reaction mixture was filtered and washed with MeOH and hot H2O. 
The dark precipitate was purified by repeated column chromatography (silica, eluent: 
CH2Cl2/MeOH = 98/2). 1.06 g of crude product (still containing traces of propionic 
acid, as well as several polymeric compounds) yielded 371 mg (0.3 mmol, 22%) of the 
purified tetrakis(p-(phtalimidomethyl)phenyl)porphyrin. 
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2)   Condensation of aldehyde and dipyrromethane 
 
4-(formylbenzyl)phtalimide (80 mg, 0.3 mmol) and 4-(formylbenzyl)phtalimidyl 
dipyrromethane (115 mg, 0.3 mmol) were dissolved in CH3CN under nitrogen. After 
addition of TFA (3 µl) and stirring for 4 h, DDQ (102 mg, 0.45 mmol) was added to 
oxidize the formed porphyrinogen to porphyrin. The oxidation reaction was followed by 
HPLC, where the tetrakis(p-(phtalimidomethyl)phenyl)porphyrin had a retention time of 
28.0 min. The identity of the product was confirmed by mass spectroscopy: 1251.8 Da 
(calculated: 1252.0 Da), and the product was purified by HPLC. The reaction yield was 
31.2 mg (0.025 mmol, 16.6%). 
 
 
 
 
 
 
 
 
 
Figure 18: HPLC chromatogram and UV-VIS spectrum of tetrakis(p-( phtalimidomethyl)phenyl)-
                     porphyrin. 
 
 
 
 
 
 
 
 
Figure 19: Mass spectrum of tetrakis(p-(phtalimidomethyl)phenyl)porphyrin. 
 
Hydrolysis of the phtalimidyl groups took place by adding hydrazin (500 µl 0.01 mmol) 
to 31.2 mg (0.025 mmol) tetrakis(p-(phtalimidomethyl)phenyl)porphyrin in 8 ml THF 
to yield 16.1 mg (0.022 mmol, 89%) of tetrakis(p-(aminomethyl)phenyl)porphyrin 
(TAMPP). The reaction was monitored by HPLC, where the completely hydrolyzed 
porphyrin had a retention time of 17.2 min. After purification by HPLC, the identity of 
the product was confirmed by mass spectroscopy: 732.6 Da (calculated: 731.7 Da). 
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Figure 20: HPLC chromatogram and UV-VIS spectrum of tetrakis(p-(aminomethyl)phenyl)porphyrin.  
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Mass spectrum of tetrakis(p-(aminomethyl)phenyl)porphyrin. 
 
3.3.7 Partial protection with Boc 
 
To obtain porphyrins which are partially protected with Boc, 14.1 mg (0.01 mmol) of  
tetrakis(p-(aminomethyl)phenyl)porphyrin was dissolved in 10 ml DMF and 2 
equivalents of Boc-O-Su (4.3 mg, 0.02 mmol) were added. Subsequently, DIEA was 
added till pH ~ 9/10. The result was a mixture of partially protected porphyrins. The 
ratio between the various porphyrin compounds could be manipulated by changing the 
ratio porphyrin/Boc-O-Su. 
The various porphyrins were purified by HPLC and the identity of the different products 
was determined by mass spectroscopy (shown in table 2). NMR spectra were registered 
to establish the identity of the cis and trans isomers. The trans porphyrin eluted 3 
minutes before the cis, which rendered the purification relatively easy. The purified 
products were chemically stable and could be stored at –20 ºC for an  indefinite period 
of time. 
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         Substitution        t (min) HPLC        % CH3CN         Mass (Calcd)        Mass (Found) 
        0 Boc          17.3                      31 %                730.9 Da               731.8 Da 
        1 Boc                     22.1                      42 %                831.0 Da               832.4 Da 
    2 Boc trans               25.6                      50 %                931.1 Da               932.4 Da 
     2 Boc cis                  28.5                      50 %                931.1 Da               932.4 Da 
        3 Boc                     33.3                      66 %              1031.3 Da             1032.5 Da 
        4 Boc     38.9                      90 %              1131.4 Da             1131.1 Da 
 
 
Table 2: Results of the reaction between TAMPP and Boc-O-Su, showing the retention time, elution 
                percentage of acetonitrile and results of mass spectrum. 
 
 
 
 
 
 
Chapter 4  Functionalization of the scaffolds 
 
Introduction 
 
The porphyrin scaffolds have been functionalized with three different peptides: Fmoc-
Chg-Arg(Pbf)-2Nal-OH, 2Noa-Ser(tBu)-Glu(tBu)-Thr(tBu)-Met-OH and HO-Succ-Pro-
Glu(tBu)-Tyr(tBu)-Asp(tBu)-Pro-Chg-OH. The functionalized scaffolds have been 
named according to the type of porphyrin: tetraphenylporphyrin (TPP) or 
tetrakis(p-aminomethylphenyl)porphyrin (TAMPP). The tripeptide H-Chg1-Arg2-2Nal3-
OH was designed to interact with the thrombin catalytic site (CS), whereas the 
pentapeptide 2Noa-Ser1-Glu2-Thr3-Met4-OH and the heptapeptide HO-Succ-Pro1-Glu2-
Tyr3-Asp4-Pro5-Chg6-OH were designed interact with the thrombin exo site (ES). The 
peptides will therefore be indicated as follows: CS3 (tripeptide), ES5 (pentapeptide) e 
ES7 (heptapeptide). Insertion of manganese(II) yielded MnIII complexes, as most 
MnII-porphyrin complexes are unstable in the presence of dioxygen132,133. The following 
functionalized scaffolds were synthesized: 
 
Mono-functionalized TPP compounds: 
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Bi-functionalized TAMPP compounds: 
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MnIII-porphyrin complexes: 
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4.1       Results 
 
4.1.1       Synthesis of the peptides 
 
The following peptides were synthesized: 
 
CS3 :  H-Chg1-Arg2-2Nal3-OH 
ES5 :  2Noa-Ser1-Glu2-Thr3-Met4-OH 
ES7 :  HO-Succ-Pro1-Glu2-Tyr3-Asp4-Pro5-Chg6-OH 
 
To avoid side reactions during the coupling of the peptides to the scaffold, fully 
protected peptides were synthesized using Fmoc solid phase peptide synthesis 
(SPPS)134,135. This peptide synthesis protocol consists of anchoring of the first amino 
acid to the resin, followed by deprotection of the Fmoc protecting group in 20% 
piperidine in DMF, coupling of the next amino acid using 3 equivalents of the activators 
PyBop and HOBt in the presence of 6 equivalents of DIEA, and subsequent 
deprotection of the new Fmoc protecting group. The resin of choice for all four 
synthesized peptides was the 2-chloro-tritylchloride resin (shown in figure 1). This resin 
allows cleavage of the peptide from the resin while leaving all protecting groups on the 
side-chains, as well as on the N-terminal residue, intact136,137. 
 
                
C Cl
 
 
Figure 1: Resin 2-chloro-tritylchloride 
 
Anchoring of the first amino acid on the 2-chloro-tritylchloride resin took place in DMF 
in the presence of 2,5 equivalents of DIEA. The 2-chloro-tritylchloride groups that did 
not react with the amino acid were blocked by MeOH. Final cleavage of the peptide 
from the resin took place in a CH2Cl2 solution containing 10% acetic acid and 10% 
trifluoroethanol (TFE). 
 
The N-terminal amino acid of the peptides could be either Boc or Fmoc protected, as 
the porphyrin scaffolds were found to be stable in both deprotection reactions (50% 
TFA in CH2Cl2/DMF for deprotection of Boc, 20% piperidine in CH2Cl2/DMF for 
deprotection of Fmoc). In fact, the tripeptide H-Chg-Arg(Pbf)-2Nal-OH was 
synthesized with Fmoc-Chg-OH as well as with Boc-Chg-OH as N-terminal amino 
acid, and the coupling to the porphyrin scaffold was performed with both peptides to 
prove the stability of the scaffold during the deprotection reaction. In the case of these 
particular peptides, having acid-labile side chain protecting groups, the presence of the 
Boc-protected peptide meant one less deprotection step, since the Boc protecting group 
could be removed together with the other protecting groups in a mixture of TFA and 
scavengers. However, it was important to determine the stability of the scaffolds in all 
possible conditions, to ascertain the possibility to use these extremely versatile scaffolds 
for other applications in which the peptide sequence might dictate a different use of 
protecting groups. For the synthesis of the three peptides the following amino acids 
were used:  
 
CS3:   Fmoc-Nal-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Chg-OH / Boc-Chg-OH. 
ES5:   Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Thr(tBu)-OH,    
           and 2-naphtyloxyacetic acid (Noa, see figure 2). 
ES7:   Fmoc-Chg-OH, 2 Fmoc-Pro-OH, Fmoc-Asp(tBu)-OH, Fmoc-Tyr(tBu)-OH,  
           Fmoc-Glu(tBu)-OH, and succinic anidride (Succ). 
 
O
OH
O
 
 
Figure 2: Structure of napthyloxyacetic acid 
 
The peptides CS3 and ES5 were synthesized on a 0.25 mmol scale, using resin 
substitutions varying from 0.55 to 0.65 mmol/g. When the original resin substitution 
was significantly higher, the substitution was lowered to the desired amount by using a 
deficient amount of peptide for the anchoring of the first amino acid. After cleavage of 
the resin the products were pure and did not require further purification. The peptides 
were obtained as white solids with an average yield of 85%. 
 
The hexapeptide H-Pro-Glu(tBu)-Tyr(tBu)-Asp(tBu)-Pro-Chg-OH was synthesized on a 
0.1 mmol scale, with a resin substitution of 0.86 mmol/g. After completion of the 
synthesis, a small part of the resin (2.0 mg) was taken apart and cleavage was performed 
to confirm the identity and purity of the product. The peptide ES7 was designed to 
interact with the thrombin exo site by its C-terminal end, therefore it had to be linked to 
the porphyrin scaffold by its N-terminal end. Succinic acid was chosen as an opportune 
spacer, and was introduced by bubbling the resin with a DMF solution containing 4% 
pyridine and 4.7% succinic anhydride. The peptide was not cleaved from the resin, 
since that would yield a peptide bearing two free carboxyl groups, while only the N-
terminal end of the peptide had to be activated to react with the porphyrin scaffold. 
Therefore, activation of the peptide and coupling to the scaffold took place with the 
peptide still attached to the resin, and cleavage was performed only after the coupling 
reaction was complete. 
 
4.1.2 Activation of the peptides 
 
Peptide synthesis protocols usually employ activants such as PyBop, DCC, HOBt, 
HATU, or HBTU in the presence of DIEA, to activate the free carboxyl groups and 
perform the coupling reaction to the next amino acid138. Essentially the coupling 
reaction between the amine groups of the porphyrin scaffols and the carboxyl ends of 
the peptides should be the same as the coupling of two amino acids. However, 
difficulties were encountered when these activants were used for linking the synthesized 
peptides to the porphyrin scaffolds. It has been impossible to create reaction conditions 
for the functionalization reaction to take place using these activants, even when a single 
amino acid was used instead of the peptide. Therefore, the problem seemed to lie in the 
structure of the porphyrin scaffold, more specifically in the elevated hygroscopicity of 
the tetrakis(p-(aminomethyl)phenyl)porphyrin. It is known that the merest presence of 
water inactivates the herefore mentioned activants, which explains why the coupling 
reaction could not take place.  
Since the porphyrin scaffold could not be easily obtained in complete absence of water, 
a different approach was used to link the peptides to the scaffold. The peptides were 
activated by N-hydroxysuccinimide139, an activant that nowadays is not often employed. 
This activant allows the activation of the peptide carboxyl groups (in absence of water) 
and isolation of the activated product, while the second step, the coupling of the 
activated peptide to the free amine group, can take place in a variety of solvents, 
including water. Therefore, the presence of a small amount of water, due to the 
hygroscopicity of the porphyrin scaffold, does not interfere with the linking of the 
peptide to the scaffold. 
 
The carboxyl groups of the peptides CS3 and ES5 were activated by N-
hydroxysuccinimide in the presence of dicyclohexylcarbodiimide according to the 
following scheme: 
 
Figure 3: Activation of the carboxyl group of a peptide (R) with N-hydroxysuccinimide in the presence of 
                dicyclohexylcarbodiimide. 
 
The activation reaction took place at 4 ºC. After stirring the peptide with the 
N-hydroxysuccinimide for 10 min, 1 equivalent of dicyclohexylcarbodiimide (DCC) 
was added. The reaction was complete after 24-36 h, the product was purified by HPLC 
and could be stored at -20 ºC for an indefinite period of time. For the peptide ES7 the 
activation took place while the peptide was still attached to the resin, by adding excess 
(3 eq) of both N-hydroxysuccinimide and DCC to the resin and bubbling with nitrogen 
for 24 h. A small part of the resin was taken apart and the peptide was cleaved to 
confirm the completion of the activation reaction. 
 
4.1.3 Functionalization of the scaffolds 
 
The coupling reaction between the activated peptide and the porphyrin scaffold took 
place according to the following scheme: 
 
 
 
 
 
 
 
Figure 4: Reaction of the activated peptide (R) with the amine group of the porphyrin scaffold in the  
                 presence of triethylamine 
 
The reaction took place in CH2Cl2/DMF at room temperature. Triethylamine was added 
till pH ~ 9/10. The proceeding of the reaction was followed by TLC and RP-HPLC. 
After completion of the reaction, usually after 15-20 min, the product was purified 
either by chromatography on silica gel or by HPLC.  
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For the synthesis of bi-functionalized porphyrin compounds, two different approaches 
were possible. One possibility was to protect one of the free amine groups (for example 
with a Fmoc or Boc protecting group), so the first activated peptide could be added 
without formation of the dimer; the other possibility was to use no protecting groups, so 
a deficient amount of the activated peptide had to be added in order to avoid formation 
of the dimer. In this last case, it would not be possible to obtain a 100% yield of the 
mono-functionalized porphyrin. However, if one of the amine groups was protected, the 
protecting group would have to be removed after linking of the first peptide, without 
disturbing the protecting groups present on this peptide. Also, additional 
protection/deprotection/purification steps usually caused a small loss of the 
intermediates, resulting in lower yields. Therefore, it was decided to perform the 
synthesis of the bi-functionalized compounds without additional protecting groups, in 
order to avoid unnecessary loss of product. Even though the first functionalization step 
did not have a 100% yield, the starting compounds could be easily recovered and used 
in subsequent syntheses. Both CS3-TAMPP-ES5 and CS3-TAMPP-ES7 had the 
tripeptide Boc-Chg-Arg(Pbf)-2Nal-OH in common. For the CS3-TPP-ES7 the 
heptapeptide had to be linked to the scaffold while being still attached to the resin, so it 
was a logical choice to add first the tripeptide, and then the second (hepta)peptide. Even 
though there was no particular reason to favour one or other of the peptides in the case 
of CS3-TPP-ES5, the same procedure was followed, consisting of linking first the 
tripeptide and afterwards the second (penta)peptide.  
The mono-functionalized porphyrins CS3-TPP, TPP-ES5, CS3-TAMPP, TAMPP-ES5 
and TAMPP-ES7 were synthesized with an average yield of 80%. For the bi-
functionalized porphyrins, the linking of the first peptide had an average yield of 45%, 
whereas the coupling of the second peptide usually had yields of 70-80%, resulting in 
overall yields of 30-35%. 
 
The deprotection of the protecting groups took place at 0 ºC in the following mixture: 
 
   9 eq   trifluoroacetic acid (TFA) 
   1 eq   thioanisole  
0.6 eq   ethanedithiol (EDT) 
0.3 eq   ß-mercapto-ethanol 
0.2 eq   anisole 
 
The thiol-based scavengers were added to avoid any side reactions that might occur 
when the protecting groups were removed from the peptide side chains. For the 
compounds containing only the peptide ES5 or ES7, the deprotection was usually 
complete after 1 h, when the peptide CS3 was present reaction times of 2-3 h were 
necessary, due to the presence of the Pbf protecting group which required a prolonged 
reaction time. After completion of the reaction the solvent was evaporated, the major 
part of the scavengers was removed by extraction with diethyl ether, and the product 
was further purified by HPLC. Average yields were 60-70%. 
 
4.1.4 Insertion of manganese in the peptide-porphyrin compounds 
 
For the insertion of manganese, the previously mentioned acetate method was used (see 
paragraph 1.2.2). The reaction took place in a 50% solution of acetic acid in methanol, 
using manganese(II) acetate as metal provider140. Upon insertion of the metal in the 
porphyrin ring, the MnII ion was oxidized to MnIII. During the reaction the colour of the 
reaction mixture changed from green to brown/green, indicating the formation of the 
manganese(III) porphyrin complex. The reaction was monitored by HPLC and UV-VIS, 
where slowly the characteristic MnIII-porphyrin spectrum became dominant141 (see 
figure 5). After circa 20 h the reaction was complete and the product was purified by 
HPLC. 
 
 
 
 
 
 
 
 
 
Figure 5: UV-VIS spectrum of  the MnIII-complexes of CS3-TAMPP-ES5 and CS3-TAMPP-ES7 in 
                EtOH. 
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4.2 Discussion 
 
The functionalization of the previously synthesized porphyrin scaffolds was successful 
in all cases. It was found that peptides had to be activated by N-hydroxysuccinimide, 
since other activants, such as PyBop, HOBt, HATU did not produce the desired results. 
It was shown that the functionalization reaction could take place either in solution, or 
with the activated peptide still attached to the resin. Both Fmoc and Boc protected 
peptides could be used for functionalization of the scaffolds, as the versatile porphyrin 
scaffolds proved to be stable in both deprotection protocols. The functionalization 
reaction could take place either in solution or with the activated peptide still attached to 
the resin. The straightforward synthesis and work-up using HPLC or column 
chromatography lead to stable, chemically pure compounds. Removal of the protecting 
groups took place using a mixture of scavengers in TFA, to avoid undesired alteration 
of the peptide-porphyrin compound. When stored at -20 ºC, the peptide-functionalized 
porphyrin compounds could be kept for an indefinite period of time. Average yields 
were 80-90% for the mono-functionalized compounds and 30-35% for the bi-
functionalized compounds. However, in the case of the bi-functionalized scaffolds, part 
of the starting compound used in the first functionalization step could be recovered and 
used to repeat the reaction, so the actual yields were much higher. 
Insertion with manganese took place using MnIIAc2 in a 50% acetic acid/MeOH 
solution, upon which MnIII-porphyrin complexes were formed. Since the peptide-
porphyrin compounds had the tendency to aggregate in aqueous solutions, all extinction 
coefficients were determined in ethanol. 
 
4.3 Experimental section 
 
4.3.1 Materials and methods 
 
Unless otherwise stated, solvents of anhydroscan grade were used for all reactions. 
Reagents were obtained from commercial suppliers and used as received. All 
manipulations and reactions were carried out using standard Schlenk techniques. Solid 
phase peptide synthesis was performed manually in a 20 ml reactor. Analysis of 
reaction mixtures and products was performed by TLC on silica, or by using a RP-
HPLC Shimadzu system LC-10AD VP with a spectrophotometric detector Diode Array 
SPD-M10A VP. Linear gradients were used of H2O 0.1% TFA and CH3CN 0.1% TFA. 
UV-VIS spectra were recorded with a Varian Cary 5000 spectrophotometer. Mass 
spectrometry was carried out on a Voyager DEPRO MALDI-TOF spectrometer 
(Applied Biosystems) in the linear mode, using bovine insulin as internal calibration 
standard. The matrix α-cyano-4-hydroxycinnamic acid was recrystallized from EtOH / 
H2O prior to use. 
 
4.3.2 Synthesis of the peptides 
 
Synthesis of the tripeptide Fmoc-Chg-Arg(Pbf)-2Nal-OH 
 
The substitution of the resin was 0.64 mmol/g, the reaction scale 0.25 mmol. The 
following amino acids were used: Fmoc-Nal-OH, Fmoc-Arg(Pbf)-OH and Fmoc-Chg-
OH. As shown by the HPLC chromatogram, after cleavage from the resin, the product, 
with a retention time of 25.98 min, was pure and did not require further purification. 
The identity of the product was determined by mass spectroscopy: 985.62 Da 
(calculated 984.0 Da). After evaporation of the solvent the peptide was dissolved in 
H2O 0.1% TFA and CH3CN 0.1% TFA, and freeze-dried to obtain 206.6 mg of a white 
solid (0.21 mmol, 84 %). 
 
 
 
 
 
 
 
Figure 6: HPLC chromatogram and UV-VIS spectrum of Fmoc-Chg-Arg(Pbf)-2Nal-OH. 
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Figure 7: Mass spectrum of Fmoc-Chg-Arg(Pbf)-2Nal-OH. 
 
Synthesis of the tripeptide Boc-Chg-Arg(Pbf)-2Nal-OH 
 
The original substitution of the resin was 1.69 mmol/g. By adding a deficient amount of 
the first amino acid followed by capping with MeOH, the substitution was lowered to 
0.65 mmol/g. The reaction scale was 0.25 mmol. The following amino acids were used: 
Fmoc-Nal-OH, Fmoc-Arg(Pbf)-OH and Boc-Chg-OH. As shown by the HPLC 
chromatogram of the product after cleavage from the resin, the product was pure and 
did not require further purification. The identity of the product was determined by mass 
spectroscopy: 884.2 Da (calculated: 861.8 Da, 884.2 Da = M+Na+). After evaporation 
of the solvent, the peptide was dissolved in H2O 0,1% TFA and CH3CN 0,1% TFA, and 
freeze-dried to obtain 203 mg of a white solid (0.236 mmol, 94.4%). 
 
 
 
 
 
 
 
 
Figure 8: HPLC chromatogram and UV-VIS spectrum of Boc-Chg-Arg(Pbf)-2Nal-OH. 
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Figure 9: Mass spectrum of Boc-Chg-Arg(Pbf)-2Nal-OH. 
 
Synthesis of the pentapeptide 2Noa-Thr(tBu)-Glu(tBu)-Ser(tBu)-Met-OH 
 
The substitution of the resin was 0.55 mmol/g, the reaction scale 0.25 mmol. The 
following amino acids were used: Fmoc-Met-OH, Fmoc-Ser(tBu)-OH, Fmoc-Glu(tBu)-
OH, Fmoc-Thr(tBu)-OH and 2-naphtyloxyacetic acid. As shown by the HPLC 
chromatogram of the product after cleavage from the resin, the product was pure and 
did not require further purification. The identity of the product was determined by mass 
spectroscopy: 842.1 Da (calculated: 819.0 Da, 842.1 Da = M+Na+). After evaporation 
of the solvent, the peptide was dissolved in H2O 0.1% TFA and CH3CN 0.1% TFA, and 
freeze-dried to obtain 160 mg of a white solid (0.20 mmol, 78%). 
 
 
 
 
 
 
 
 
Figure 10: HPLC chromatogram and UV-VIS spectrum of 2Noa-Thr(tBu)-Glu(tBu)-Ser(tBu)-Met-OH. 
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4Figure 11: Mass spectrum of 2Noa-Thr(tBu)-Glu(tBu)-Ser(tBu)-Met-OH 
 
Synthesis of HO-Succ-Pro-Glu(tBu)-Tyr(tBu)-Asp(tBu)-Pro-Chg-OH 
 
The substitution of the resin was 0.86 mmol/g, the reaction scale 0.1 mmol. The 
following amino acids were used: Fmoc-Chg-OH, Fmoc-Pro-OH, Fmoc-Asp(tBu)-OH, 
Fmoc-Tyr(tBu)-OH and Fmoc-Glu(tBu)-OH. To confirm the identity of the hexapeptide 
H-Pro-Glu(tBu)-Tyr(tBu)-Asp(tBu)-Pro-Chg-OH, a small part of the resin (2.0 mg) was 
taken apart and cleavage of the peptide from the resin was performed using 10 ml 
CH2Cl2/TFE/HAc = 8/1/1 for 30 min. The HPLC chromatogram showed the presence of 
one major product, of which the identity was determined by mass spectroscopy: 949.5 
Da (calculated 927.15 Da, 949.5 Da = M+Na+). 
  
 
 
 
 
 
 
Figure 12: HPLC chromatogram and UV-VIS spectrum of the hexapeptide H-Pro-Glu(tBu)-Tyr(tBu)-
                   Asp(tBu)-Pro-Chg-OH. 
 
 
 
 
 
 
 
 
Figure 13: Mass spectrum of the hexapeptide H-Pro-Glu(tBu)-Tyr(tBu)-Asp(tBu)-Pro-Chg-OH. 
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 Since this peptide was designed to bind the amine group of the porphyrin scaffold with 
its N-terminal end, succinic acid was introduced at the N-terminus of the peptide by 
bubbling the resin with a 4% pyridine 4.7% succinic anhydride DMF solution, for 15 
min, repeated two times. Again, a small part of the resin (2.0 mg) was taken apart to 
confirm the formation of the desired product. Cleavage of the peptide from the resin 
was performed using 10 ml CH2Cl2/TFE/HAc = 8/1/1 for 30 min. The HPLC 
chromatogram showed the presence of one major product, of which the identity was 
determined by mass spectroscopy: 1049.2 Da (calculated 1026.2 Da, 1049.2 Da = 
M+Na+). The peptide remained attached to the resin. 
 
 
 
 
 
 
 
Figure 14: HPLC chromatogram and UV-VIS spectrum of HO-Succ-Pro-Glu(tBu)-Tyr(tBu)-Asp(tBu)-
                  Pro-Chg-OH. 
 
 
 
 
 
 
 
 
 
Figure 15: Mass spectrum of HO-Succ-Pro-Glu(tBu)-Tyr(tBu)-Asp(tBu)-Pro-Chg-OH. 
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4.3.3 Activation of the peptides 
 
Activation of the tripeptide Fmoc-Chg-Arg(Pbf)-2Nal-OH 
 
10.2 mg (0.01 mmol) of the Fmoc-tripeptide was dissolved in 6 ml CH2Cl2, after which 
1.2 mg (1 eq) of N-hydroxysuccinimide was added. After stirring for 10 min at 4 ºC, 21 
µl 0.5 M (1 eq) of DCC in CH2Cl2 was added slowly to the reaction mixture. After 24 h 
at 4 ºC, a white precipitate (N,N’-dicyclohexylurea) had formed. The HPLC 
chromatogram showed the presence of a new peak with a retention time of ~1,1 min 
more than the original peptide. The identity of the product was determined by mass 
spectroscopy: 1104.5 Da (calculated 1081.1 Da, 1104.49 Da = M+Na+). The activated 
peptide was purified by HPLC and freeze-dried to obtain 7.8 mg of a white solid (0.007 
mmol, 72%).  
 
 
 
 
 
 
 
 
 
 
Figure 16: Mass spectrum of the activated Fmoc-Chg-Arg(Pbf)-2Nal-N-Su. 
 
Activation of the tripeptide Boc-Chg-Arg(Pbf)-2Nal-OH 
 
21.5 mg (0.025 mmol) of the Boc-tripeptide was dissolved in 10 ml CH2Cl2, after which 
2.88 mg (1 eq) of N-hydroxysuccinimide was added. After stirring for 10 min at 4 ºC, 
50 µl 0.5 M (1 eq) of DCC in CH2Cl2 was added slowly to the reaction mixture. After 
24 h at 4 ºC a white precipitate had formed. The HPLC chromatogram showed the 
presence of a new peak with a retention time of ~1,4 min more than the original peptide. 
The identity of the product was determined by mass spectroscopy: 982.8 Da (calculated 
959.0 Da, 982.8 Da = M+Na+). The activated peptide was purified by HPLC and freeze-
dried to obtain 18.2 mg of a white solid (0.019 mmol, 76%). 
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Figure 17: Mass spectrum of the activated Boc-Chg-Arg(Pbf)-2Nal-N-Su. 
 
Activation of the pentapeptide 2Noa-Thr(tBu)-Glu(tBu)-Ser(tBu)-Met-OH 
 
12.3 mg (0.015 mmol) of the pentapeptide was dissolved in 10 ml CH2Cl2, after which 
1.73 mg (1 eq) of N-hydroxysuccinimide was added. After stirring for 10 min at 4ºC, 30 
µl 0.5 M (1 eq) of DCC in CH2Cl2 was slowly added to the reaction mixture. After 24 h 
at 4ºC a white precipitate was formed. The HPLC chromatogram showed the presence 
of a new peak with a retention time of ~1,4 min more than the original peptide. The 
identity of the product was determined by mass spectroscopy: 955.2 Da (calculated 
916.0 Da, 955.2 Da = M+K+). The activated peptide was purified by HPLC and freeze-
dried to obtain 9.34 mg of a white solid (0.010 mmol, 68%). 
 
 
 
 
 
 
 
 
 
Figure 18: Mass spectrum of the activated 2Noa-Thr(tBu)-Glu(tBu)-Ser(tBu)-Met-N-Su. 
 
Activation of HO-Succ-Pro-Glu(tBu)-Tyr(tBu)-Asp(tBu)-Pro-Chg-OH 
 
While bubbling with N2, a solution of 10 mg (0.087 mmol, 10 eq) N-
hydroxysuccinimide in 10 ml of CH2Cl2/DMF = 1/1 was added at room temperature to 
22.8 mg di resin (8.7 µmol peptide, substitution = 0.38 mmol/g). After 10 min, 200 µl 
0.5 M DCC in CH2Cl2 (1.1 eq) was added, after which the solution was kept for 24 h. 
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The resin was washed 5 times with CH2Cl2/DMF and dried with N2. The activated 
peptide remained attached to the resin. 
 
4.3.4 Coupling of the peptides to the porphyrin scaffolds 
 
Mono-functionalized scaffolds 
 
Synthesis of CS3-TPP                                          
 
1.6 mg (2.5 µmol) tetrakis(p-aminomethylphenyl)porphyrin and 1 eq (2.7 mg) activated 
Fmoc-Chg-Arg(Pbf)-Nal-N-Su were dissolved in a mixture of CH2Cl2/DMF (50/50). 
Triethylamine was added till pH ~ 9/10 (approximately 1.5 µl). After 15 min, the HPLC 
chromatogram showed that the starting porphyrin at 20.4 min had almost completely 
disappeared, and a new porphyrin had appeared with retention time 31.0 min. The 
identity of this product was confirmed by mass spectroscopy to be the desired CS3-TPP 
(protecting groups included): 1633.8 Da (calculated 1609.8 Da; 1633.8 Da corresponds 
to the sodium salt of CS3-TPP). The product was purified by HPLC and freeze-dried to 
obtain 3.0 mg (2.0 µmol, 79%) of a green solid. 
The first deprotection reaction involved the removal of the Fmoc group in 20% 
piperidine in DMF. The reaction was followed by TLC (silica, eluent CH2Cl2/MeOH = 
9/1), where the protected CS3-TPP had RF = 0.58. After 30 min the reaction was 
complete: the starting compound had disappeared and a new compound had formed 
with RF = 0.3. The solvent was removed in vacuo, after which the remaining Pbf 
protecting group was removed by dissolving the product in 4 ml of the earlier described 
cleavage mixture (see paragraph 4.1.3) and stirring for 2 h. The reaction was followed 
by HPLC, where slowly a new porphyrin appeared at retention time 22.9 min. When the 
reaction was complete, the solvent was evaporated, the product washed several times 
with diethyl ether to remove the major part of the scavengers, purified by HPLC and 
freeze-dried to obtain 2.5 mg (1,6 µmol, 80%) of a green solid. The mass spectrum 
confirmed the identity of the completely deprotected CS3-TPP: 1137.7 Da (calculated 
1137.5 Da). 
  
 
 
 
 
 
Figure 19: HPLC chromatogram and UV-VIS spectrum of CS3-TPP. 
 
 
 
 
 
 
 
 
Figure 20: Mass spectrum of CS3-TPP. 
 
Synthesis of TPP-ES5 
 
0.64 mg (1.0 µmol) p-aminomethyltetraphenylporphyrin and 1 eq (0.92 mg) activated 
ES5 were dissolved in a mixture of CH2Cl2/DMF (50/50). Triethylamine was added till 
pH ~ 9/10 (approximately 0.7 µl). After 15 min, the TLC (eluent: CH2Cl2/MeOH = 9/1) 
showed that the starting porphyrin (RF = 0.2) had disappeared, whereas a new porphyrin 
had appeared with RF = 0.5). The same tendency was observed in the HPLC 
chromatogram, where the starting porphyrin at 20.4 min had almost completely 
disappeared, and a new porphyrin had appeared at retention time 31.1 min. The product 
was purified by HPLC and freeze-dried to obtain 1.2 mg (0.7 µmol, 70%) of a green 
solid. 
The protecting groups were removed by dissolving the product in 4 ml of the earlier 
described cleavage mixture (see paragraph 4.1.3) and stirring for 1 h. The reaction was 
followed by HPLC, where slowly a new porphyrin appeared at retention time 21.8 min. 
When the reaction was complete, the solvent was evaporated, the product washed 
several times with diethyl ether to remove the major part of the scavengers, purified by 
HPLC and freeze-dried to obtain 0.8 mg (0.53 µmol, 75%) of a green solid. The mass 
spectrum confirmed the identity of the completely deprotected TPP-ES5: 1293.7 Da 
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(calculated 1276.8 Da, 1293.7 Da corresponds to TPP-ES5 with the methionine residue 
oxidized to Met(O)). 
 
 
 
 
 
 
Figure 21: HPLC chromatogram and UV-VIS spectrum of TPP-ES5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Mass spectrum of TPP-ES5. 
 
Synthesis of CS3-TAMPP   
 
4.6 mg (3.4 µmol) 3Boc-TAMPP and 1 eq (3.2 mg) activated Boc-tripeptide were 
dissolved in a mixture of CH2Cl2/DMF (50/50). Triethylamine was added till pH ~ 9/10 
(approximately 1,4 µl). After 15 min, the TLC (eluent: CH2Cl2/MeOH = 9/1) showed 
that the starting porphyrin (RF = 0,2) had disappeared, whereas a new porphyrin had 
appeared with RF = 0.5). The same tendency was observed in the HPLC chromatogram, 
where the starting porphyrin had almost completely disappeared, and a new porphyrin 
had appeared at retention time 28.6 min. The product was purified by column 
chromatography (silica gel, eluent CH2Cl2/MeOH = 9/1). After evaporation of the 
solvent, 5.61 mg (3.0 µmol, 90%) of a dark red solid was obtained.  
The protecting groups were removed by dissolving the product in 4 ml of the earlier 
described cleavage mixture (see paragraph 4.1.3) and stirring for 2 h. The reaction was 
followed by HPLC, where slowly a new porphyrin appeared at retention time 22.0 min. 
When the reaction was complete, the solvent was evaporated, the product washed 
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several times with diethyl ether to remove the major part of the scavengers, purified by 
HPLC and freeze-dried to obtain 4.89 mg (1.6 µmol, 80%) of a green solid. The mass 
spectrum confirmed the identity of the completely deprotected CS3-TAMPP: 1223.9 Da 
(calculated 1223.0 Da). 
     
 
 
 
 
 
 
 
Figure 23: HPLC chromatogram and UV-VIS spectrum of CS3-TAMPP. 
 
 
 
 
 
 
 
 
 
Figure 24: Mass spectrum of CS3-TAMPP. 
 
The extinction coefficient of the pure CS3-TAMPP was determined by measuring the 
absorbance at 416 nm of different concentrations of CS3-TAMPP in ethanol. The 
resulting graph of absorbance versus concentration is shown in figure 26. The extinction 
coefficient ε416 nm is calculated to be 3.4·105 L·M-1·cm-1. 
 
 
 
 
 
 
 
 
 
Figure 25: The extinction coefficient of CS3-TAMPP. 
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Synthesis of TAMPP-ES5  
 
4.6 mg (3.4 µmol) 3Boc-TAMPP and 1 eq (3.1 mg) activated pentapeptide were 
dissolved in a mixture of CH2Cl2/DMF (50/50). Triethylamine was added till pH ~ 9/10 
(approximately 1.4 µl). After 15 min, the TLC (eluent: CH2Cl2/MeOH = 9/1) showed 
that the starting porphyrin (RF = 0.2) had disappeared, whereas a new porphyrin had 
appeared with RF = 0.5). The same tendency was observed in the HPLC chromatogram, 
where the starting porphyrin had almost completely disappeared, and a new porphyrin 
had appeared at retention time 28.2 min. The product was purified by column 
chromatography (silica gel, eluent CH2Cl2/MeOH = 9/1). After evaporation of the 
solvent, 4.8 mg (2.3 µmol, 69%) of a dark red solid is obtained. The protecting groups 
were removed by dissolving the product in 3 ml of the earlier described cleavage 
mixture (see paragraph 4.1.3) and stirring for 1 h. The reaction was followed by HPLC, 
where slowly a new porphyrin appeared at retention time 21.9 min. When the reaction 
was complete, the solvent was evaporated, the product washed several times with 
diethyl ether to remove the major part of the scavengers, purified by HPLC and freeze-
dried to obtain 3.2 mg (2.0 µmol, 87%) of a green solid. The mass spectrum confirmed 
the identity of the completely deprotected TAMPP-ES5: 1379.6 Da (calculated 1364.0 
Da, 1379.6 Da = Met(O)). 
 
 
 
 
 
 
 
 
Figure 26: HPLC chromatogram and UV-VIS spectrum of TAMPP-ES5. 
 
 
 
 
 
 
 
 
Figure 27: Mass spectrum of TAMPP-ES5. 
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Synthesis of TAMPP-ES7  
 
2.5 mg (1.8 µmol) 3Boc-TAMPP dissolved in 10 ml CH2Cl2/DMF were added to 10 mg 
of resin containing 3.7 µmol of activated peptide ES7. Triethylamine was added till pH 
~ 9/10 (approximately 6.0 µl). After 60 min the resin was washed several times with 
DMF and CH2Cl2. The colour of the resin had changed from yellow to red, indicating 
the presence of the porphyrin scaffold on the resin. Cleavage of the peptide-porphyrin 
compound took place by bubbling a solution of CH2Cl2/TFE/acetic acid = 8/1/1 for 30 
min, repeated two times. After washing the resin several times with CH2Cl2, the 
fractions were reunited and the solvent was evaporated under vacuo.The TLC (eluent: 
CH2Cl2/MeOH = 9/1) showed that the starting porphyrin (RF = 0.2) had disappeared, 
whereas a new porphyrin had appeared with RF = 0.35). The same tendency was 
observed in the HPLC chromatogram, where the starting porphyrin had almost 
completely disappeared, and a new porphyrin had appeared at retention time 27.1 min. 
The product was purified by column chromatography (silica gel, eluent CH2Cl2/MeOH 
= 9/1). After evaporation of the solvent, 2.26 mg (1.3 µmol, 72 %) of a dark red solid is 
obtained. The protecting groups were removed by dissolving the product in 3 ml of the 
earlier described cleavage mixture (see paragraph 4.1.3) and stirring for 1 h. The 
reaction was followed by HPLC, where slowly a new porphyrin appeared at retention 
time 19.85 min. When the reaction was complete, the solvent was evaporated, the 
product washed several times with diethyl ether to remove the major part of the 
scavengers, purified by HPLC and freeze-dried to obtain 1.88 mg (1.2 µmol, 92 %) of a 
green solid. The mass spectrum confirmed the identity of the completely deprotected 
TAMPP-ES7: 1569,1 Da (calculated 1568.2 Da). 
 
 
 
 
 
 
 
 
Figure 28: HPLC chromatogram and UV-VIS spectrum of TAMPP-ES7. 
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Figure 29: Mass spectrum of TAMPP-ES7. 
 
Bi-functionalized TPP compounds 
 
Synthesis of cis-CS3-TPP-ES5 
 
10 mg (8.8 µmol) of 5,10-diphenyl-15,20-bis(p-(aminomethyl)phenyl)porphyrin and 
5 eq (5.2 µl) TEA were dissolved in 10 ml CH2Cl2/DMF. A solution of 7.7 mg (7.1 
µmol, 0.8 eq) Fmoc-Chg-Arg(Pbf)-2Nal-N-Su in 1,0 ml CH2Cl2/DMF was slowly 
added to the reaction mixture, while at regular intervals the proceeding of the reaction 
was checked by TLC (silica, eluent CH2Cl2/MeOH = 9/1). The starting porphyrin had 
RF = 0.0, the mono-functionalized porphyrin had RF = 0.2. After addition of ~ 0.6 eq of 
the peptide, a small amount of the dimer (RF = 0.5) started to form, and the reaction was 
stopped. In the HPLC chromatogram the mono-functionalized porphyrin cis-CS3-TPP-
NH2 had a retention time of 27.7 min, the bi-functionalized porphyrin cis-2CS3-TPP 
had a retention time of 34.6 min. The mass spectrum confirmed the identity of the 
protected cis-CS3-TPP-NH2: 1641.7 Da (calculated 1640.0 Da). The solvent was 
evaporated in vacuo, the product was purified by HPLC and freeze-dried to obtain 2.16 
mg of a green solid (1.1 µmol, 13%). 
The second peptide was added by dissolving 2.2 mg (1.1 µmol) of CS3-TPP-NH2 and 
1.21 mg (1 eq) of activated pentapeptide in 4 ml CH2Cl2/DMF. Subsequently 0.9 µl (5 
eq) of TEA was added and the reaction was monitored by TLC (silica, eluent 
CH2Cl2/MeOH = 9/1). Only one product was formed, with RF = 0.6, which was purified 
by column chromatography (silica gel, eluent CH2Cl2/MeOH = 9/1). After evaporation 
of the solvent 2.1 mg (0.87 mmol, 79%) of a dark red solid was obtained. 
 
In the first deprotection reaction the Fmoc group was removed in a solution of 20% 
piperidine in DMF. After 30 min, the HPLC chromatogram showed the disappearance 
of the starting compound and the formation of a new compound with a retention time of 
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29.0 min. The solvent was evaporated, after which the remaining protecting groups 
were removed by dissolving the product in 3 ml of the earlier described cleavage 
mixture (see paragraph 4.1.3) and stirring for 2 h. The reaction was followed by HPLC, 
where slowly a new porphyrin appeared at retention time 21,6 min. When the reaction 
was complete, the solvent was evaporated, the product washed several times with 
diethyl ether to remove the major part of the scavengers, purified by HPLC and freeze-
dried to obtain 1.2 mg (0.52 µmol, 60%) of a green solid. The mass spectrum confirmed 
the identity of the completely deprotected CS3-TPP-ES5: 1814.0 Da (calculated 1797.2 
Da; 1814.0 Da corresponds to CS3-TPP-ES5 containing oxidized methionine Met(O)). 
 
 
 
 
 
 
 
 
Figure 30: HPLC chromatogram and UV-VIS spectrum of CS3-TPP-ES5. 
 
 
 
 
 
 
 
 
 
Figure 31: Mass spectrum of CS3-TPP-ES5. 
  
Synthesis of cis CS3-TAMPP-ES5 
 
11.5 mg (8.3 µmol) of cis-2Boc-TAMPP and 5 eq (5.8 µl) TEA were dissolved in 4 ml 
CH2Cl2/DMF. A solution of 7.95 mg (1 eq) activated Boc-tripeptide in 1.0 ml CH2Cl2 
was slowly added to the reaction mixture, while at regular intervals the proceeding of 
the reaction was checked by TLC (silica, eluent CH2Cl2/MeOH = 85/15). The starting 
porphyrin had RF = 0,  whereas the mono-functionalized porphyrin had RF = 0.45. After 
addition of ~ 0.6 eq of the peptide, a small amount of the dimer (RF = 0.8) started to 
form, and the reaction was stopped. In the HPLC chromatogram the mono-
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functionalized porphyrin cis-CS3-TAMPP-2Boc had a retention time of 25.5 min, the 
di-functionalized porphyrin cis-2CS3-TAMPP-2Boc had a retention time of 30.9 min. 
The mass spectrum confirmed the identity of the protected cis-CS3-TAMPP-2Boc: 
1776.5 Da (calculated 1775.0 Da). The solvent was evaporated in vacuo, the product 
was purified by HPLC and freeze-dried to obtain 8.2 mg of a green solid (3.9 µmol, 
47%). 
The cis-CS3-TAMPP-2Boc (8.2 mg, 3.9 µmol) was dissolved  in 4 ml CH2Cl2/DMF and 
3.6 mg (1 eq) of activated pentapeptide was added, together with 2.2 µl (5 eq) of TEA. 
The reaction was followed by TLC (silica, eluent CH2Cl2/MeOH = 85/15). Only one 
product with RF = 0.9 was formed, which was purified by column chromatography 
(silica gel, eluent CH2Cl2/MeOH = 85/15). After evaporation of the solvent 8.2 mg (3.2 
mmol, 82%) of a dark red solid was obtained. The HPLC chromatogram confirmed the 
presence of one product, with a retention time of 30.8 min. 
 
The protecting groups were removed by dissolving the product in 4ml of the earlier 
described cleavage mixture (see paragraph 4.1.3) and stirring for 2 h. The reaction was 
followed by HPLC, where slowly a new porphyrin appeared at retention time 24.7 min. 
When the reaction was complete the solvent was evaporated, and the product was 
washed several times with diethyl ether to remove the major part of the scavengers, 
purified by HPLC and freeze-dried to obtain 4.3 mg (1.7 µmol, 53%) of a green solid. 
The mass spectrum confirmed the identity of the completely deprotected CS3-TAMPP-
ES5: 1870.3 Da (calculated 1855.0 Da; 1870.3 Da corresponds to CS3-TAMPP-ES5 
containing oxidized methionine Met(O)). 
 
 
 
 
 
 
 
 
 
Figure 32: HPLC chromatogram and UV-VIS spectrum of CS3-TAMPP-ES5. 
Spectrum at time 24,68 min.
nm
200 400 600 800
m
AU
0
200
400
m
AU
0
200
400
24,68 min
Minutes
0 10 20 30 40
m
AU
0
100
200
300
m
AU
0
100
200
300
3: 434 nm, 8 nm
79B prep fraz3+5 26-09-05
82 prep fraz3+5 26-09-05 24,69 min 436 nm 
24,69 min 
mAU 
  
 
 
 
 
 
 
Figure 33: Mass spectrum of CS3-TAMPP-ES5. 
 
The extinction coefficient of the pure CS3-TAMPP-ES5 compound was determined by 
measuring the absorbance at 416 nm of different concentrations of CS3-TAMPP-ES5 in 
ethanol. The resulting graph of absorbance versus concentration is shown in figure 34. 
The extinction coefficient ε416 nm is calculated to be 3.9·105 L·M-1·cm-1.            
                     
 
 
 
 
 
 
 
Figure 34: The extinction coefficient of CS3-TAMP-ES5. 
 
Synthesis of trans CS3-TAMPP-ES7 
 
9.3 mg (6.7 µmol) of trans-2Boc-TAMPP and 5 eq (4.7 µl) TEA were dissolved in 10 
ml CH2Cl2/DMF. A solution of 7.0 mg (1 eq) activated Boc-tripeptide in 1.0 ml 
CH2Cl2/DMF was slowly added to the reaction mixture, while at regular intervals the 
proceeding of the reaction was checked by TLC (silica, eluent CH2Cl2/MeOH = 85/15). 
The starting porphyrin had RF = 0,  the mono-functionalized porphyrin had RF = 0.55. 
After addition of ~ 0.6 eq of the peptide, a small amount of the dimer (RF = 0.9) started 
to form, and the reaction was stopped. In the HPLC chromatogram the mono-
functionalized porphyrin trans-CS3-TAMPP-2Boc had a retention time of 24.9 min, the 
bi-functionalized porphyrin trans-2CS3-TAMPP had a retention time of 30.3 min. The 
mass spectrum confirmed the identity of the protected trans-CS3-TAMPP-2Boc: 1776.3 
Da (calculated 1775.1 Da). The solvent was evaporated in vacuo, the product was 
purified by HPLC and freeze-dried to obtain 5.9 mg of a green solid (2.8 µmol, 42%). 
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The second (hepta)peptide was linked to the porphyrin scaffold while still attached to 
the resin. The trans-CS3-TAMPP-2Boc (5.9 mg, 3.4 µmol) was dissolved in 10 ml 
CH2Cl2/DMF and added to 13.4 mg of resin (substitution 0.38 mmol) containing 5.1 
µmol (2 eq) of activated heptapeptide. Triethylamine was added till pH ~ 9/10 
(approximately 2.0 µl). After 1 h of bubbling with N2, the resin was washed several 
times with CH2Cl2/DMF. The colour of the resin had changed from yellow to pink, 
indicating the presence of the porphyrin scaffold on the resin. Cleavage of the peptide-
porphyrin compound took place by bubbling a solution of CH2Cl2/TFE/acetic acid = 
8/1/1 for 30 min, repeated two times. After washing the resin several times with 
CH2Cl2, the fractions were reunited and the solvent was evaporated under vacuo. In the 
HPLC chromatogram, the starting porphyrin compound had disappeared and a new 
porphyrin had appeared at retention time 29.5 min. The product was slightly 
contaminated by excess of peptide (retention time 22.3 min), the major part of which 
was removed by column chromatography (silica gel, eluent: first CH2Cl2 100%, 
subsequently CH2Cl2/MeOH = 9/1). Even though the product was not completely pure, 
no problems were encounterd during the deprotection reaction, after which total 
purification took place. 
 
The protecting groups were removed by dissolving the product in 4 ml of the earlier 
described cleavage mixture (see paragraph 4.1.3) and stirring for 2 h. The reaction was 
followed by HPLC, where slowly a new porphyrin appeared at retention time 22.8 min. 
When the reaction was complete, the solvent was evaporated, the product was washed 
several times with diethyl ether to remove the major part of the scavengers, purified by 
HPLC and freeze-dried to obtain 2.47 mg (0.94 µmol, 34%) of a green solid. The mass 
spectrum confirmed the identity of the completely deprotected CS3-TAMPP-ES7: 
2065.8 Da (calculated 2064.3 Da). 
 
 
 
 
 
 
 
 
Figure 35: HPLC chromatogram and UV-VIS spectrum of CS3-TAMPP-ES7. 
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Figure 36: Mass spectrum of CS3-TAMPP-ES7. 
 
4.3.5 Insertion of manganese 
 
Synthesis of cis MnIII-CS3-TAMPP-ES5 
 
5.5 mg (2.2 µmol) of CS3-TAMPP-ES5 was dissolved in 4 ml 50% acetic acid in 
MeOH. MnAc2.4H2O was added (10 eq, 5.3 mg) and stirring was continued overnight. 
The reaction mixture turned slowly brown-green, and the HPLC chromatogram showed 
the presence of a new peak at 22.9 min with the characteristic UV spectrum of a MnIII-
porphyrin complex. The product was purified by HPLC, after which 2.93 mg (1.23 
µmol, 57%) of a dark green solid was obtained. The mass spectrum confirmed the 
identity of the desired product: 1924.8 Da (calculated 1925.0 Da). 
 
 
 
 
 
 
 
 
 
Figure 37: HPLC chromatogram and UV-VIS spectrum of MnIII-CS3-TAMPP-ES5. 
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Figure 38: Mass spectrum of Mn-CS3-TAMPP-ES5. 
 
The extinction coefficient of the pure MnIII-CS3-TAMPP-ES5 complex was determined 
by measuring the absorbance at 467 nm of different concentrations of MnIII-CS3-
TAMPP-ES5 in ethanol. The resulting graph of absorbance versus concentration is 
shown in figure 39. The extinction coefficient ε at 467 nm is calculated to be 
8.9·104 L·M-1·cm-1.             
 
 
 
 
 
 
 
 
 
Figure 39: The extinction coefficient of MnIII-CS3-TAMPP-ES5 
 
The value of ε467 nm was confirmed by atomic adsorption and corresponds with values 
found in literature of MnIII-porphyrin complexes142. 
 
Synthesis of cis MnIII-CS3-TAMPP-ES7 
 
2.0 mg (1.0 µmol) of CS3-TAMPP-ES7 was dissolved in 3 ml 50% acetic acid in 
MeOH. MnAc2.4H2O was added (10 eq, 2.4 mg) and stirring was continued overnight. 
The reaction mixture turned slowly brown-green, and the HPLC chromatogram showed 
the presence of a new peak at 22.1 min with the characteristic UV spectrum of a MnIII-
porphyrin complex. The product was purified by HPLC, after which 1.01 mg (0.51 
µmol, 51%) of a dark green solid was obtained. The mass spectrum confirmed the 
identity of the desired product: 2117.3 Da (calculated 2117.3 Da). 
Extinction coefficient of Mn(III)-CS3-TAMPP-ES5 
-1 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
0.00E+00 2.00E-05 4.00E-05 6.00E-05 8.00E-05 1.00E-04 
Conc [M] 
Abs 
(467 nm) 
1143.0 1520.4 1897.8 2275.2 2652.6 3030.0
Mass (m/z)
0
946.6
0
10
20
30
40
50
60
70
80
90
100
%
 
In
te
n
si
ty
Voyager Spec #1=>NF0.7[BP = 379.7, 14860]
1923.49
1945.54
1871.99
1859.80
1924,7  (M) 
% Intensity 
Mass Mass (m/z) 
  
 
 
 
 
 
 
 
Figure 40: HPLC chromatogram and UV-VIS spectrum of MnIII-CS3-TAMPP-ES7. 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Mass spectrum of Mn-CS3-TAMPP-ES7.
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Chapter 5  Tests of inhibition of human α-thrombin 
 
Introduction 
 
The TAMPP-based functionalized scaffolds resulted to be more soluble in H2O than 
their TPP counterparts. The functionalized TAMPP scaffolds were therefore more 
suitable as potential inhibitors, since all inhibition tests of thrombin took place in 
aqueous solutions, usually in Tris buffer of pH = 7.8. Highly concentrated stock 
solutions were prepared in either ethanol or DMSO. The following functionalized 
scaffolds were studied for their specificity of binding to human α-thrombin: 
 
Mono-functionalized TAMPP compounds: 
 
    
 
 
 
 
 
                CS3-TAMPP                                    TAMPP-ES5                                     TAMPP-ES7                                                                 
 
 
Bi-functionalized TAMPP compounds: 
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MnIII-porphyrin complexes: 
 
 
 
 
 
 
 
 
 
              MnIII-CS3-TAMPP-ES5                                                  MnIII-CS3-TAMPP-ES7 
 
The mono-functionalized compounds were used to establish the interaction of the 
individual peptides with thrombin, and to measure their contribution to the inhibition of 
thrombin proteolytic activity. The following tests were performed: 
 
- Inhibition of the catalytic activity  
- Stability of the inhibitors to enzymatic degradation 
- Selectivity of the inhibitors for different proteolytic enzymes 
- Interaction with the exo site 
- Inhibition of clot-bound thrombin 
 
Specific low molecular weight substrates have been developed for thrombin, consisting 
of peptides mimicking the amino acid sequence adjacent to the substrate’s cleavage site 
(the α-chain of fibrinopeptide A). Usually, these peptide-based synthetic substrates 
present chromogenic or fluorogenic groups to facilitate monitoration of the cleavage 
reaction143. The first synthetic substrates that have been developed for the enzymes 
thrombin, trypsin and plasmin were para-nitro-anilide containing peptides. A p-nitro-
aniline (pNA) group is added to these peptides, in order to produce a chromogenic 
product after cleavage. Examples of highly specific substrates for α-thrombin are Bz-
Phe-Val-Arg-pNA.HCl (also known as S-2160), H-D-Phe-Pip-Arg-pNA.2HCl (S-2238), 
Z-Gly-Pro-Arg-pNA.HCl (Cbz-Chromozym TH) and Tos-Gly-Pro-Arg-pNA.HCl (Tos-
Chromozym TH or Chromozym TH).  
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Figure 1:  Structure of Tosyl-glycyl-L-prolyl-L-arginine p-nitroanilide (Chromozym TH). 
 
Tos-Chromozym TH is less specific than the Cbz-derivative, but has a higher sensibility 
towards thrombin and is therefore mainly used in hydrolytic assays. Another advantage 
of these small synthetic substrates is that they also react with the hydrolysed ß and γ 
forms of thrombin, with only a small loss of catalytic activity. In fact, mixtures of α, ß 
and γ thrombin still retain up to 94% of the initial catalytic activity towards Chromozym 
TH144,145. 
5.1 Results 
 
5.1.1 Calculation of Km 
 
The substrate Tos-Gly-Pro-Arg-p-nitro-anilide (Chromozym TH) was used for the 
inhibition test of the catalytic site. Cleavage of the Arg-nitroanilide bond yielded p-
nitroaniline, which had a strong absorption at 405 nm. The affinity constant Km was 
calculated by measuring the velocity of substrate hydrolysis at different substrate 
concentrations (from 10 to 100 µM).   
 
 
 
 
 
 
 
 
Figure 2: Graph of absorbance at 405 nm vs time, showing the hydrolysis of the substrate Chromozym 
                 TH by human α-thrombin at different substrate concentrations. 
 
 
 
 
 
 
 
 
Figure 3: Graphs of V vs [S] and 1/V vs 1/[S] (Lineweaver-Burk plot). Calculation of Km. 
 
Hydrolysis of the chromogenic substrate catalyzed by human α-thrombin showed a Km 
value of 20.0 µM under our experimental conditions, which agrees well with values 
reported in literature146. 
 
100 µM 
90 µM 
80 µM 
70 µM 
60 µM 
50 µM 
40 µM 
30 µM 
20 µM 
10 µM 
V / [S] 
0
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0 20 40 60 80 100 
[S] (µM) 
V 
1/V - 1/[S] 
-1 
0
1 
2
3
4
5
6
-0.1 -0.05 0 0.0 0.1 0.15 
1/[S
1/V 
-1/Km 
5.1.2 Inhibition of the catalytic site 
 
To be able to compare the experimental data of the new inhibitors with known 
inhibitors, the exact same procedure of the inhibition test has been performed using the 
inhibitor Hirunorm II. Hirunorm II has a known inhibition constant Ki of 8.45 nM4. In 
our experiments, using substrate concentrations of 40 and 125 µM at inhibitor 
concentrations ranging from 0 to 80 nM, an inhibition constant Ki of 16.3 nM has been 
found (as shown in figure 4). 
 
 
 
 
 
 
 
Figure 4: Dixon plot of human α thrombin inhibition by Hirunorm II at substrate  
 concentrations of 40 and 125 µM. 
 
The inhibition constants Ki for the hydrolysis of Chromozym TH by the new porphyrin-
based inhibitors are reported in table 1. The inhibition tests were not performed with 
inhibitors TAMPP-ES5 and TAMPP-ES7, as these were designed to interact with the 
thrombin fibrinogen recognition site, and not with the catalytic site. Initial rate 
velocities were recorded and used to construct Dixon plots (shown in figure 5). 
 
 
                Compound                      Ki (µM) 
 
               CS3-TAMPP                        1.04 
   
           CS3-TAMPP-ES5                    1.01 
 
           CS3-TAMPP-ES7                    1.04      
 
       MnIII-CS3-TAMPP-ES5              1.63 
 
Table 1: Inhibition constants of the new inhibitors 
 
The inhibitors all showed inhibition constants in the micromolar range, with a slightly 
higher value for the MnIII-inhibitor complex MnIII-CS3-TAMPP-ES5. The Ki values are 
significantly higher than for the Hirunorm compounds, which exhibit inhibition 
constants in the nanomolar and even picomolar range. However, the fact that these 
inhibitors were capable to inhibit the hydrolysis of the substrate Chromozym TH, 
indicated that the tripeptide CS3 was capable to interact with the thrombin catalytic site 
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as was intended. Surprisingly, the presence or not of the second peptide, ES5 or ES7, 
designed to interacted with the thrombin exo-site, does not seem to have any major 
effect on the activity of the catalytic site.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:  Dixon plots of human α-thrombin inhibition by the new inhibitors.  Each point represents 
                 the average of  triplicate determinations. Substrate concentrations are:  
 
 
The slightly higher Ki value of the manganese(III) complex of CS3-TAMPP-ES5 is 
probably due to the presence of the positively charged metal ion in the hydrophobic 
pocket that accomodates the porphyrin macrocycle. Apparently, the metal ion partly 
disrupts the hydrophobic interactions between the porphyrin ring and the thrombin 
surface. 
 
5.1.3 Stability of the inhibitors 
 
The stability of the inhibitors CS3-TAMPP-ES5 and CS3-TAMPP-ES7 against 
enzymatic degradation by thrombin was tested by incubation of the inhibitors with 
thrombin at 37 ºC. The HPLC chromatograms, registered after 24 h of incubation, 
showed that more than 85% of the original compound was still present in the incubation 
mixture. Therefore, the new inhibitors resulted to be very stable in the presence of 
thrombin, compared to hirulog-1 that is known to be rapidly degradated (100% after 30 
min with 1.6 NIH/ml thrombin)147. 
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Figure 6: HPLC chromatograms of the incubation mixtures of CS3-TAMPP-ES5 and CS3-TAMPP-ES7 
                after 24 h. 
 
5.1.4 Selectivity of the inhibitors 
  
Apart from its inhibition constant, another important feature of an inhibitor is its 
selectivity. In order to be useful as a specific thrombin inhibitor, it should not have a 
major inhibition effect on other proteases of the same family, not even at elevated 
concentrations. To test the selectivity of the newly synthesized inhibitors, bovine trypsin 
inhibition was assayed using benzoylarginine ethyl ester (BAEE) as substrate148:  
 
 
 
 
 
 
The reactions were initiated by addition of trypsin to the incubation mixture, containing 
the substrate in phosphate buffer and the inhibitor at concentrations up to 10 µM. The 
change in absorbance was recorded continuously at 253 nm. As is shown in figure 5, the 
new inhibitors did not affect the hydrolysis of the substrate by trypsin, not even at high 
concentrations. The inhibitors could therefore be considered highly specific for 
thrombin. 
 
 
 
 
 
 
 
 
Figure 7: Hydrolysis of BAEE by trypsin in the presence of inhibitors CS3-TAMPP and CS3-TAMPP-
                 ES5 at concentrations of 0, 1, 5 and 10 µM. The presence of the inhibitors does not affect the 
                 hydrolysis rate. 
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Figure 8: Hydrolysis of BAEE by trypsin in the presence of inhibitor MnIII-CS3-TAMPP-ES5 at 
                  concentrations of 0, 1, 5 and 10 µM. The presence of the inhibitor does not affect the 
                   hydrolysis rate. 
 
5.1.5 Interaction with the exo site  
 
The interaction of the peptides ES5 and ES7 with the thrombin exo site was assayed by 
measuring the fluorescence intensity of thrombin at an excitation wavelength of 290 
nm, when only the tryptophan residues of the protein contribute to the fluorescence. 
Residue Trp148 is positioned in close proximity of the exo site, therefore upon inhibitor 
binding, the Trp side chain is supposed to be involved in hydrophobic interactions with 
the porphyrin macrocycle (see paragraph 2.5.2). The fluorescence of this Trp residue 
should be quenched by the presence of the inhibitor, and the total fluorescence of 
thrombin should diminish. To ascertain that the change of fluorescence is due to this 
particular Trp residue, the thrombin-inhibitor complex was treated with N-acetyl-
hirudin54’-65’ (IRU-1), a potent inhibitor of thrombin with a high affinity for the exo site, 
that should be able to replace the porphyrin-based inhibitor at the exo site. The change 
in the fluorescence intensity of thrombin in the presence of the compounds TAMPP-
ES5 and TAMPP-ES7 is shown in figure 9. Upon addition of TAMPP-ES5 or TAMPP-
ES7, the fluorescence intensity diminished, whereas upon subsequent addition of IRU-1 
the fluorescence was almost completely recovered. These results indicated that IRU-1 
displaced at least part of the porphyrin compounds from the exo site, and therefore that 
both peptides ES5 and ES7 are capable of interacting with the exo site. As expected, for 
the compound TAMPP-ES7 the change in fluorescence intensity is larger than for 
TAMPP-ES5. When the peptide ES7 interacts with the exosite, the porphyrin 
macrocycle is positioned directly above the residue Trp148.  In the case of peptide ES5 
the distance between the porphyrin macrocycle and Trp148 is greater, resulting in a 
smaller quenching effect. 
MnIII-CS3-TAMPP-ES5  0-10 µM 
  
 
 
 
 
 
 
 
 
 
Figure 9: Fluorescence assays of TAMPP-ES5 and TAMPP-ES7. Excitation wavelength 290 nm. 
                   T = thrombin, I = inhibitor, IRU = N-acetyl-hirudin54’-65’. 
 
5.1.6 Inhibition of clot-bound thrombin 
 
Fibrin clots were obtained by mixing thrombin and fibrinogen at 37 ºC, after which the 
clots were washed repeatedly to remove the free thrombin as well as any unreacted 
fibrinogen. The clots were then pre-incubated for 1 h at 37 ºC at inhibitor concentrations 
ranging from 0 to 10 µM. After repeated washing with buffer solution, the presence of 
the inhibitor on the fibrin clot was proved by the change in colour from white to yellow, 
as is shown in figure 10. 
 
    
 
Figure 10: Macroscopic view of fibrin clots before (left) and  
                 after (right) pre-incubation with 10 µM inhibitor.  
 
The ability of clot-bound thrombin to promote clot growth after pre-incubation with 
inhibitor was tested by incubating the washed clots at 37 ºC with a fresh fibrinogen 
solution. The increase in clot size was inhibited concentration-dependently by pre-
incubation with inhibitor MnIII-CS3-TAMPP-ES5, as shown in figure 11. After pre-
incubation with a 10 µM inhibitor solution, clot growth was only 60% of the growth of 
the uninibited clots. 
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Figure 11: Percentage clot growth after pre-incubation with inhibitors MnIII-CS3-TAMPP-ES5 and MnIII-
                  CS3-TAMPP-ES7.Each point is the result of six separate measurements. 
 
[I] (µM) 
Clot growth after pre-incubation with  
MnIII-CS3-TAMPP-ES5 
0 
20 
40 
60 
80 
100 
120 
0 2 4 6 8 10 12 
% clot 
growth 
Clot growth after pre-incubation with 
MnIII-CS3-TAMPP-ES7 
0 
20 
40 
60 
80 
100 
120 
0 2 4 6 8 10 12 
[I] (µM) 
% clot 
growth 
5.2 Discussion 
 
The various biological tests sofar described demonstrated that the newly synthesized 
inhibitors CS3-TAMPP-ES5 and CS3-TAMPP-ES7, as well as their MnIII-complexes, 
were able to interact with both the catalytic site and the exo site of thrombin. The mono-
functionalized porphyrin scaffolds were used to establish the interaction of the 
individual peptides with thrombin. The tests of inhibition of the catalytic site using the 
substrate Chromozym TH allowed the calculation of the inhibition constants Ki for all 
inhibitors. CS3-TAMPP, CS3-TAMPP-ES5, CS3-TAMPP-ES7 all had a Ki value of 1.0 
µM, whereas MnIII-CS3-TAMPP-ES5 had a slightly higher Ki of 1.6 µM. Surprisingly, 
the presence of the peptides ES5 and ES7 had no effect on the value of the inhibition 
constant.  
The inhibitors CS3-TAMPP-ES5 and CS3-TAMPP-ES7 resulted to be very resistant 
against enzymatic degradation by thrombin, as after 24 h 85% of the original compound 
was still intact.  
Assays of inhibition of trypsin with the substrate BAEE proved the selectivity of the 
new inhibitors, since even at elevated concentrations (up to 10 µM) the inhibitors did 
not affect the hydrolysis rate of the reaction.  
The ability of the new inhibitors to interact with the thrombin exo site by the peptides 
ES5 and ES7 was proved by fluorescence spectroscopy. The fluorescence of Trp148, in 
close proximity of the exo site, was quenched when the compounds TAMPP-ES5 and 
TAMPP-ES7 were added. Addition of IRU-1, replacing the inhibitor at the exo site, 
allowed the fluorescence intensity to return to almost the original level. For the 
compound TAMPP-ES7 this effect is more pronounced than for TAMPP-ES5, probably 
because the distance between the porphyrin macrocycle and the residue Trp148 is smaller 
in the case of TAMPP-ES7.  
The manganese(III) complexes of the inhibitors CS3-TAMPP-ES5 and CS3-TAMPP-
ES7 were capable of interacting with clot-bound thrombin, and partially inhibited clot-
growth in the presence of fresh fibrinogen. After 1h pre-incubation with a 10 µM 
inhibitor solution, clot growth was decreased to 60% compared to the uninhibited clots. 
 
5.3 Experimental section 
 
5.3.1 Materials and methods 
 
Buffer solutions were prepared in spectroscopic grade H2O supplied by Romil. The Tris 
buffer contained 0.05 M Tris-HCl, 0.1 M NaCl, 0.1% PEG 6000, and NaOH was added 
till pH = 7.8. Reagents were obtained from commercial suppliers and used as received. 
Human α-thrombin, with a specific activity of 3032 NIH units/mg protein, was supplied 
by Calbiochem, as well as fibrinogen which was dissolved in acqueous solution by 
continued stirring at 37 ºC. Chromozym TH was supplied by Roche Diagnostics. 
N-acetyl-hirudin54’-65’ (IRU-1) was previously synthesized using standard Fmoc SPPS 
protocols, and purified by RP-HPLC. Analysis of reaction mixtures was performed 
using a RP-HPLC Shimadzu system LC-10AD VP with a spectrophotometric detector 
Diode Array SPD-M10A VP. Linear gradients were used of H2O 0.1% TFA and 
CH3CN 0.1% TFA. UV-VIS spectra were recorded on a Varian Cary 5000 
spectrophotometer. Fluorescence spectra were recorded on a Jasco FP-750 
spectrofluorometer. Fibrin clots were analysed using a Zeiss Axioskop 40 optical 
microscope with an Axiocam MRc5 colour camera. 
 
5.3.2 Inhibition tests 
 
Inhibition of the catalytic site 
 
The human α-thrombin catalyzed hydrolysis of Tos-Gly-Pro-Arg-p-nitro-anilide 
(Chromozym TH) was monitored at 405 nm on a Cary 5000 spectrophotometer and 
recorded continuously as a function of time. The hydrolytic reactions were performed at 
37 ºC in 0.05 M Tris-HCl buffer, pH 7.8, containing 0.1 M NaCl and 0.1% polyethylene 
glycol 6000. The concentration of α-thrombin was determined spectrophotometrically 
using an extinction coefficient at 280 nm of 1.83 ml·mg-1·cm-1. The incubation mixtures 
contained 895 µl buffer, 5 µl 5.0·10-6 M α-thrombin (final concentration 2.5·10-8 M) and 
50 µl inhibitor in ethanol (final concentrations ranging from 0 to 1000 nM). The 
reactions were initiated by addition of 50 µl of substrate solution (final concentration 
20-150 µM). Initial rate velocities were recorded and used to construct Dixon plots. 
 
Stability of the inhibitors 
 
Resistance of the new inhibitors to the enzymatic degradation by thrombin was 
evaluated by HPLC. Thrombin (50 NIH/ml) was incubated up to 24 h at 37 ºC with 500 
nM inhibitors in Tris buffer (pH = 7.8). At regular intervals, samples were withdrawn 
and acidified with H2O 0.1% TFA before injection into the HPLC system. The HPLC 
chromatograms showed that the peptide-porphyrin compounds CS3-TAMPP-ES5 and 
CS3-TAMPP-ES7 were stable against degradation by thrombin, and that even after 24 h 
more than 85% of the compound was still intact. 
 
Selectivity of the inhibitors 
 
Bovine trypsin inhibition was assayed using benzoylarginine ethyl ester (BAEE) as 
substrate149. The assays were performed at 25 ºC in a 0.067 M sodium phosphate buffer 
at pH = 7.6. The concentration of trypsin was determined spectrophotometrically using 
an extinction coefficient at 280 nm of 1.44 ml·mg-1·cm-1.  
The incubation mixtures contained 880 µl buffer, 20 µl 6.3·10-5 M trypsin in 1.0 mM 
HCl (final concentration 1.9·10-6 M), 50 µl 1.0·10-2 M BAEE in phosphate buffer (final 
concentration 5.0·10-4 M) and 50 µl inhibitor in ethanol (final concentrations ranging 
from 0 to 10 µM). The reactions were initiated by addition of trypsin to the incubation 
mixture. The change in absorbance was recorded continuously at 253 nm.  
  
Inhibition of the exosite 
 
The fluorescence was measured at 25 ºC between 300 and 400 nm, after excitation at 
290 nm. The concentration of thrombin was 5.0·10-7 M in Tris buffer. The initial 
fluorescence was registered, an equimolar amount of inhibitor was added and the 
sample was mixed thoroughly. After measuring the fluorescence of the thrombin-
inhibitor complex, an equimolar amount of IRU-1 was added, and the fluorescence 
measurement was repeated. All assays were repeated three times. 
 
Inhibition of clot-bound thrombin 
 
Fibrin clots were prepared by adding 50 µl human α-thrombin (25 NIH units/ml) to 
mixture of 200 µl of a 5 mg/ml solution of human fibrinogen in 0.18% NaCl solution 
containing 0.01% Tween 80 (NT solution), and 25 µl of a 200 mg/ml solution of human 
albumin in water. After 15 min incubation at 37 ºC, the liquid phase was removed and 
the remaining fibrin clot was washed five times with 3 ml of NT solution to remove free 
thrombin and unreacted fibrinogen.  
The washed clots were incubated for 1 h at 37 ºC in 700 µl Tris buffer containing from 
0 to 10 µM inhibitor (MnIII-CS3-TAMPP-ES5 or MnIII-CS3-TAMPP-ES7), after which 
the liquid was removed and the clots washed three times with buffer solution in order to 
remove the free inhibitor. Fibrinogen solution (500 µl) was added and the incubation 
was repeated for another 2h.  
At the end of the incubation time, the clots were washed five times with NT solution 
and three times with acetone. Clot size was determined by weight after drying for 24 h 
in vacuo. 
 
Chapter 6      General discussions and future prospects 
 
Introduction 
 
The aim of the research described in this thesis has been the design and synthesis of 
new molecular scaffolds based on tetraphenylporphyrin, and to test the versatility of 
these scaffolds by functionalization with various peptides. An application of the 
functionalized scaffolds has been found in the design and synthesis of new inhibitors of 
thrombin, an enzyme of fundamental importance in the blood coagulation process. The 
inhibitors CS3-TAMPP-ES5, CS3-TAMPP-ES7 and their MnIII-complexes have been 
successfully synthesized, and their capacity to interact with both the catalytic site and 
the fibrinogen recognition site of thrombin has been studied. These compounds, by 
interacting specifically with clot-bound thrombin, will allow detection of fibrin clots by 
non-invasive techniques such as MRI. 
 
6.3 Functionalized tetraphenylporphyrins as versatile scaffold 
 
Tetraphenylporphyrins carrying from one to four aminomethyl groups have been 
synthesized as scaffolds. The mixed aldehyde condensation of benzaldehyde and 
4-(formylbenzyl)phtalimide in pyrrole yielded mono, di-trans, di-cis, and tri-substituted 
porphyrins, with average yields of 4-6%. To enhance the yields of the cis and trans di-
substituted porphyrins, two alternative strategies have been developed. The trans 
porphyrin was synthesized by a 2+2 condensation of 5-(4-phtalimidomethyl)phenyl-
dipyrromethane, with a yield of 7%. For the cis porphyrin a modified version of the 
ABCD-porphyrin synthesis, consisting of six steps, was applied. Although the final 
condensation reaction had an 8% yield of cis porphyrin, the entire six-step synthesis 
required several laborious purifications as well as elevated costs. Therefore, for the 
synthesis of this particular scaffold the mixed aldehyde condensation might be a better 
choice. For the synthesis of tetrakis(p-(aminomethyl)phenyl)porphyrin, two different 
methods were applied: 1) the reaction of 4-(formylbenzyl)phtalimide and pyrrole in 
propionic acid, and 2) the TFA catalyzed condensation of 4-(formylbenzyl)phtalimide 
and 5-(4-phtalimidomethyl)phenyldipyrromethane.  
Although this latter method had a lower yield (16.6% versus 22%), the reaction was 
relatively clean with almost no polymeric byproducts. The final product could therefore 
be purified by HPLC, as opposed to the repeated column chromatography that was 
required in the first strategy. Therefore, for the synthesis of tetrakis-
(p-(aminomethyl)phenyl)porphyrin, the condensation of 4-(formylbenzyl)phtalimide 
and 5-(4-phtalimidomethyl)phenyldipyrromethane is recommended. 
The aminomethyl groups of the scaffolds were protected with the Boc protecting group 
to allow a selective functionalization of the scaffold. The protected porphyrin scaffolds 
were stable and were easily purified by HPLC. The Boc protecting groups could be 
removed with a 50% solution of TFA in CH2Cl2 to yield the original scaffold without 
loss of product. 
All scaffolds were stable in a wide range of solvents and at different values of pH. 
Storage at –20 ºC for prolonged periods of time did not cause any alteration in the 
scaffolds. 
 
The functionalization of the synthesized porphyrin scaffolds with peptides was 
successful in all cases. Activation of the peptides required the use of N-hydroxy-
succinimide, since other activants, such as PyBop, HOBt, HATU did not produce the 
desired results. The functionalization reaction could take place either in solution, or 
with the activated peptide still attached to the resin. Both Fmoc and Boc protected 
peptides could be used for functionalization of the scaffolds, as the porphyrin scaffolds 
proved to be stable in both deprotection protocols. No alteration of the peptide-
porphyrin compound was observed during the synthesis. When stored at -20 ºC, the 
peptide-functionalized porphyrin compounds could be kept for a prolonged period of 
time. Average yields of the functionalization reactions were 80-90% for the mono-
functionalized compounds and 30-35% for the bi-functionalized compounds. Stable 
MnIII-porphyrin complexes were obtained by insertion of manganese using MnIIAc2 in a 
50% acetic acid/MeOH solution. 
 
6.4 New inhibitors of thrombin 
 
The inhibitors CS3-TAMPP-ES5 and CS3-TAMPP-ES7, as well as their MnIII-
complexes, were able to interact with both the catalytic site and the exo site of 
thrombin. CS3-TAMPP, CS3-TAMPP-ES5, CS3-TAMPP-ES7 all had a Ki value of 1.0 
µM, whereas MnIII-CS3-TAMPP-ES5 had a slightly higher Ki of 1.6 µM. The presence 
of the peptides ES5 and ES7 did not affect the value of the inhibition constant.  
The inhibitors resulted to be very resistant against enzymatic degradation by thrombin, 
as after 24 h 85% of the original compound was still intact. Assays of inhibition of 
trypsin with the substrate BAEE proved the high selectivity of the new inhibitors. Even 
at elevated concentrations (up to 10 µM) the inhibitors did not affect the hydrolysis rate 
of the reaction. The ability of the new inhibitors to interact with the thrombin exo site 
by the peptides ES5 and ES7 was proved by fluorescence spectroscopy. The 
fluorescence of Trp148, in close proximity of the exo site, was quenched when the 
porphyrin-based inhibitors were added. Addition of IRU-1, replacing the inhibitor at the 
exo site, allowed the fluorescence intensity to return to almost its original level.  
The manganese complexes of the new inhibitors were capable of interacting with clot-
bound thrombin, and did partly inhibit clot growth in the presence of fresh fibrinogen. 
After 1h pre-incubation with a 10 µM inhibitor solution, clot growth was decreased to 
60% compared to the uninhibited clots. The change of colour of the fibrin clot from 
white to yellow, after pre-incubation with the inhibitors, proved the presence of the 
inhibitors on the fibrin clot. 
 
To the best of our knowledge, the compounds MnIII-CS3-TAMPP-ES5 and MnIII-CS3-
TAMPP-ES7 are the first specific inhibitors of thrombin that might be employed for 
diagnostic purposes, due to the presence of a paramagnetic metal ion inside the 
porphyrin structure. The high stability against degradation by thrombin, and the high 
selectivity of these compounds make them extremely interesting for various (medical) 
applications. 
 
6.5 Suggestions for further research 
 
Since the results of the inhibition tests in vitro are very promising, the next step will be 
to test the new compounds in vivo, and to measure the MRI response of inhibitor-
containing fibrin clots. X-ray structures of the thrombin-inhibitor complexes are 
required to fully understand the specific binding mode of the new inhibitors to 
thrombin. Once these structures will be solved, new peptide chains can be designed to 
enhance the binding affinity of these compounds for thrombin.  
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